A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Reference |
|---|
| "Glioblastomas are among the most malignant tumours for which no curative treatment exists." | ( Bodmer, S; Fontana, A; Frei, K; Malipiero, U; Siepl, C, 1991) |
| "Glioblastoma is the most malignant primary brain tumor." | ( Brem, H; Martuza, RL; Mineta, T; Ojeifo, J; Takamiya, Y, 1994) |
| "Glioblastoma is one of the most malignant of all neoplasms, and often shows resistance to chemotherapy and radiation therapy." | ( Iida, T; Iwanaga, M; Kondo, T; Matsuo, T; Mori, K; Shibata, S; Urata, Y; Yasunaga, A, 1998) |
| "Glioblastomas are particularly resistant to classical antitumor treatments." | ( Chambaut-Guérin, AM; Costa, SL; Fages, C; Gauthereau, X; Lefrançois, T; Tardy, M, 2000) |
| "Glioblastomas are highly vascular malignant brain tumors that often overexpress vascular endothelial growth factor (VEGF)." | ( Lee, J; Maity, A; O'Rourke, DM; Pore, N; Solomon, D, 2000) |
| "Two biopsies from glioblastomas are directly studied by (1)H-NMR without any treatment (ex vivo NMR)." | ( Bottura, G; Fini, G; Tinti, A; Tosi, MR; Trinchero, A; Tugnoli, V, 2001) |
| "Glioblastomas are known to contain numerous genetic and physiological alterations affecting cell survival and proliferation; one of the most common alterations being platelet-derived growth factor (PDGF) autocrine signaling characterized by coexpression of PDGF and its receptor." | ( Giese, NA; Hollenbach, SJ; Israel, MA; Lokker, NA; Sullivan, CM, 2002) |
| "Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood." | ( Hamasaki, O; Kuwabara, R; Minamoto, A; Mishima, HK; Nakahara, T; Okada, K; Sakamoto, I; Watanabe, W, 2002) |
| "Glioblastoma is a life-threatening tumor in the human brain despite the fact that radio-chemotherapy inducing DNA damage has been improved in the last decade." | ( Houkin, K; Ichimiya, S; Kikuchi, T; Kondo, N; Momota, H; Sato, N; Torigoe, T; Yamaki, T, 2003) |
| "The glioblastoma is the highest dedifferentiated form of astrocytic brain tumors, which is refractory to chemotherapy in most cases." | ( Harada, K; Rittierodt, M, 2003) |
| "Glioblastoma is a lethal neoplasm resistant to conventional radiotherapy and chemotherapy." | ( Daniel, P; Frank, B; Gillissen, B; Naumann, U; Schmidt, F; Weit, S; Weller, M; Wick, W, 2003) |
| "Glioblastoma is a therapeutic challenge as a highly infiltrative, proliferative, and resistant tumor." | ( Andre, P; Christov, C; de Boüard, S; Guillamo, JS; Jouault, H; Laurent, N; Lotteau, V; Peschanski, M; Zini, R, 2004) |
| "Glioblastoma is the highest dedifferentiated form of astrocytic brain tumors, and it is refractory to chemotherapy in most cases." | ( Harada, K; Rittierodt, M; Tschernig, T, 2004) |
| "Glioblastoma is one of the most radioresistant tumors." | ( Hong, SI; Jung, KY; Kim, DW; Kim, MS; Lee, HC; Lee, SH; Park, IC; Park, MJ; Rhee, CH; Woo, SH; Yoo, H, 2004) |
| "Glioblastoma is the deadliest and most prevalent brain tumor." | ( Banik, NL; Das, A; Patel, SJ; Ray, SK, 2004) |
| "Human glioblastoma is a deadly brain tumor that is often treated with a combination of drugs." | ( Banik, NL; Patel, SJ; Ray, SK; Sribnick, EA; Sur, P, 2005) |
| "Glioblastoma is a highly angiogenic tumor with a dismal prognosis." | ( Dichgans, J; Herrlinger, U; Nägele, T; Rieger, J; Steinbach, JP; Weller, M, 2005) |
| "Glioblastoma is a highly malignant brain tumor with a high-invasive phenotype, so the prognosis is unfavorable, even in response to multidisciplinary treatment strategies." | ( Bertelli, AA; Gagliano, N; Gioia, M; Magnani, I; Moscheni, C; Torri, C, 2005) |
| "Glioblastomas are among the most difficult neoplasms to treat with continued poor prognosis for long-term survival." | ( Higashikubo, R; Jiang, Z; Lytle, RA; Rich, KM; Zheng, X, 2005) |
| "Surgical cure of glioblastomas is virtually impossible and their clinical course is mainly determined by the biologic behavior of the tumor cells and their response to radiation and chemotherapy." | ( Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD, 2005) |
| "Glioblastomas are the most frequent and the most aggressive primary brain tumors in adults." | ( Benouaich-Amiel, A; Delattre, JY; Simon, JM, 2005) |
| "Glioblastoma is a highly malignant brain tumor with a highly invasive phenotype and hence an unfavorable prognosis even in response to multidisciplinary treatment strategies." | ( Bertelli, AA; Gagliano, N; Gioia, M; Magnani, I; Moscheni, C; Nowicky, W; Torri, C, 2006) |
| "Glioblastomas are a rich source of immunosuppressive molecules which may interfere with immune recognition and rejection as well as clinical strategies of active immunotherapy." | ( Naumann, U; Weller, M; Wick, W, 2006) |
| "Malignant glioblastoma is one of the most common malignant tumors in the neurological system." | ( Cao, WD; Cheng, G; Gao, DK; Jin, BQ; Tang, HF; Wang, XL; Zhang, X; Zhang, XH; Zhang, Y, 2006) |
| "Glioblastomas are highly vascularized tumors and anti-angiogenic strategy is one of the most promising therapeutic approaches to treat brain tumors." | ( Groves, MD; Jeon, JW; Kang, CM; Kim, JH; Kim, JT; Kim, MH; Kim, YJ; Nam, DH; Park, K; Park, SY; Son, MJ; Song, HS, 2006) |
| "Malignant glioblastoma is one of the most common malignant tumors in the neurological system." | ( Cao, WD; Cheng, G; Gao, DK; Tang, HF; Wang, XL; Zhang, X; Zhang, Y, 2006) |
| "Glioblastomas are intrinsically resistant to conventional radiation therapy." | ( Gewirtz, DA; Quick, QA, 2006) |
| "Glioblastoma is the most common and highly malignant brain tumor." | ( Banik, NL; Das, A; Hajiaghamohseni, LM; Haque, A; Ray, SK; Younger, A, 2007) |
| "Because glioblastomas are highly invasive primary brain tumors that can originate from astrocytes, we explored the involvement of PEA-15 in the control of astrocyte migration." | ( Beuvon, F; Canton, B; Chneiweiss, H; De Bouard, S; Iturrioz, X; Junier, MP; Léonard, N; Mouhamad, S; Ramos, JW; Renault-Mihara, F; Sharif, A, 2006) |
| "Glioblastomas are widely characterised by the mutation of the p53 gene and p53 disruption sensitizes glioblastoma cells to DNA topoisomerase I (TOPO I) inhibitor-mediated apoptosis." | ( Chianese, M; Cimmino, G; Laus, G; Penitente, R; Pepe, S; Prece, D; Quesada, P, 2007) |
| "Glioblastomas are malignant brain tumors that are rarely curable, even with aggressive therapy (surgery, chemotherapy, and radiation)." | ( Cerniglia, GJ; Gupta, AK; Maity, A; Pore, N, 2006) |
| "Glioblastoma is the most common primary brain tumour with poor overall survival." | ( Ng, WH; Too, HP; Wan, GQ, 2007) |
| "Glioblastomas are the most malignant gliomas with median survival times of only 15 months despite modern therapies." | ( Hau, P; Hegi, ME; Stupp, R, 2007) |
| "Glioblastoma is the most common astrocytic brain tumor in humans." | ( Banik, NL; Karmakar, S; Patel, SJ; Ray, SK, 2007) |
| "Glioblastomas are high-risk primary brain tumors that are generally unresponsive or only weakly responsive to the currently available antineoplastic agents." | ( Deeb, D; Dulchavsky, SA; Gao, X; Gautam, SC; Jiang, H; Liu, Y, 2007) |
| "Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide." | ( Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR, 2007) |
| "Glioblastomas are malignant brain tumors that are very difficult to cure, even with aggressive therapy consisting of surgery, chemotherapy, and radiation." | ( Bernhard, EJ; Cerniglia, GJ; Georgescu, MM; Gupta, AK; Hahn, SM; Jiang, Z; Maity, A; Mick, R; Pore, N, 2007) |
| "Glioblastoma is the most malignant human brain tumor that shows poor response to existing therapeutic agents." | ( Banik, NL; Karmakar, S; Ray, SK, 2007) |
| "Glioblastoma is the deadliest brain tumor in humans." | ( Banik, NL; Karmakar, S; Ray, SK, 2007) |
| "Glioblastoma is the most malignant and common type of brain tumor with devastating outcome." | ( Banik, NL; Haque, A; Ray, SK, 2007) |
| "Glioblastoma is the deadliest and most prevalent brain tumor, which is not yet amenable to any treatments." | ( Banik, NL; Das, A; Ray, SK, 2007) |
| "Glioblastoma is the most prevalent and highly malignant brain tumor that continues to defy current treatment strategies." | ( Banik, NL; Karmakar, S; Patel, SJ; Ray, SK, 2007) |
| "Glioblastoma is a highly malignant tumor, characterized by an unfavorable prognosis even in response to multidisciplinary treatment strategies, owing to its high-invasive phenotype." | ( Costa, F; Donetti, E; Gagliano, N; Gioia, M; Magnani, I; Moscheni, C; Nowicky, W; Torri, C, 2007) |
| "Glioblastomas are a type of malignant brain tumor and are among the most difficult cancers to treat." | ( Cunningham, C; Magro, AD; Magro, AM; Miller, MR, 2007) |
| "Glioblastoma is the most malignant and prevalent brain tumor in humans." | ( Banik, NL; Janardhanan, R; Ray, SK, 2008) |
| "Glioblastoma is the deadliest brain tumor that remains incurable." | ( Banik, NL; Das, A; Ray, SK, 2009) |
| "Glioblastoma is both the most common and most aggressive primary brain tumor." | ( Chamberlain, MC; Mrugala, MM, 2008) |
| "Glioblastomas are notorious for resistance to therapy, which has been attributed to DNA-repair proficiency, a multitude of deregulated molecular pathways, and, more recently, to the particular biologic behavior of tumor stem-like cells." | ( Cairncross, JG; de Tribolet, N; Delorenzi, M; Dietrich, PY; Domany, E; Gorlia, T; Hainfellner, JA; Hamou, MF; Hegi, ME; Heppner, FL; Janzer, RC; Kouwenhoven, MC; Lambiv, WL; Migliavacca, E; Murat, A; Regli, L; Shay, T; Stupp, R; Wick, W; Zimmer, Y, 2008) |
| "As glioblastomas are characterized by high expression levels of anti-apoptotic Bcl-2 family proteins, we studied the effects of the novel Bcl-2 inhibitor, ABT-737, on malignant glioma cells." | ( Böck, BC; Campos, B; Farhadi, M; Fassl, A; Herold-Mende, C; Kraemer, A; Macher-Goeppinger, S; Radlwimmer, B; Roth, W; Tagscherer, KE; Wiestler, OD, 2008) |
| "As glioblastoma are resistant to the cytotoxic effect of TNFalpha, we investigated the potential of Ebselen in sensitizing glioma cells to TNFalpha-induced apoptosis." | ( Joseph, C; Sen, E; Sharma, V; Sk, UH; Tewari, R, 2008) |
| "Glioblastoma is a malignant astrocytic tumor with a median survival of about 12 months for which new therapeutic strategies are required." | ( Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP, 2008) |
| "Glioblastoma is the most common central nervous system tumor, is associated with high morbidity and mortality, and responds poorly to surgical, chemical, and radiation therapy." | ( Eling, TE; Kamitani, H; Watanabe, T; Yoshioka, H, 2008) |
| "Glioblastoma is the most malignant brain tumor in humans and an average survival of glioblastoma patients hardly exceeds 12 months." | ( Banik, NL; Ray, SK; Zhang, R, 2008) |
| "Malignant glioblastoma is one of the highest proliferative and invasive tumors within the central nervous system (CNS); the therapeutical options for this disease are still very poor." | ( Limonta, P; Mai, S; Montagnani Marelli, M; Moretti, RM; Müller, O; Van Groeninghen, JC, 2009) |
| "Glioblastoma is the most common and aggressive form of primary brain tumor." | ( de Groot, J; Milano, V, 2009) |
| "Surgical removal of glioblastomas is challenging due to their infiltrative growth pattern." | ( Cadosch, D; Fournier, JY; Gautschi, OP; Hildebrandt, G; van Leyen, K, 2009) |
| "Glioblastomas are known to invade outside the contrast-enhancing area." | ( Jensen, TR; Schmainda, KM, 2009) |
| "Glioblastoma is a highly lethal neoplasm with a median survival of 12-14 months; only 2-5% of patients survive >3 years." | ( Inoue, T; Kanamori, M; Kumabe, T; Nakazato, Y; Sonoda, Y; Tominaga, T; Watanabe, M, 2009) |
| "Human glioblastoma is a deadly brain cancer that continues to defy all current therapeutic strategies." | ( Banik, NL; Das, A; Ray, SK, 2010) |
| "Glioblastoma is a highly vascularised tumour with a high expression of both vascular endothelial growth factor (VEGF) and VEGFR." | ( Brandes, AA; Gorlia, T; Hau, P; Kros, JM; Lacombe, D; Mirimanoff, RO; Stupp, R; Tosoni, A; van den Bent, MJ, 2010) |
| "Glioblastoma are known to be highly resistant to chemotherapy." | ( Bonnet, D; Dontenwill, M; Leger, DY; Maglott, A; Martin, S; Martinkova, E; Stiborova, M; Takeda, K, 2010) |
| "Glioblastoma is the most common type of primary brain tumor and is rapidly progressive with few treatment options." | ( Brown, C; Buettner, R; Hedvat, M; Jensen, M; Jove, R; Schroeder, A; Scuto, A; Starr, R; Yang, F, 2010) |
| "Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF)." | ( Ancukiewicz, M; Batchelor, TT; Benner, T; Chea, H; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Eichler, AF; Exarhopoulos, A; Gerstner, E; Hochberg, FH; Ivy, P; Jain, RK; Loeffler, JS; Louis, DN; Moses, MA; Plotkin, SR; Sorensen, AG; Wen, PY, 2010) |
| "Glioblastoma is the most common primary malignant brain tumor; however, glioblastoma in children is less common than in adults, and little is known about its clinical outcome in children." | ( Ahn, HS; Cho, BK; Kim, DG; Kim, IH; Kim, SK; Lee, JY; Park, SH; Phi, JH; Song, KS; Wang, KC, 2010) |
| "The prognosis of glioblastoma is better in children than in adults." | ( Ahn, HS; Cho, BK; Kim, DG; Kim, IH; Kim, SK; Lee, JY; Park, SH; Phi, JH; Song, KS; Wang, KC, 2010) |
| "Glioblastoma is the most common primary brain tumor, with typical histopathologic findings, pseudopalisading necrosis, and microvascular proliferation, all of which are associated with a poor prognosis." | ( Chi, SG; Chung, YG; Kang, SH; Park, DH; Park, KJ; Yu, MO, 2010) |
| "Glioblastoma is one of the most frequent primary brain tumors and is characterized by aggressive clinical behavior and biologic heterogeneity." | ( Jung, S; Jung, TY; Kim, HS; Kim, KJ; Lee, KH; Lee, MC; Moon, KS, 2011) |
| "Human malignant glioblastomas are highly invasive tumors." | ( Hibner, U; Kaminska, B; Kijewska, M; Kwiatkowska, A; Lipko, M, 2011) |
| "Glioblastoma is the most common primary brain tumor with a dismal prognosis, highlighting the need for novel treatment strategies." | ( Bangert, A; Cristofanon, S; Debatin, KM; Fulda, S; Häcker, S, 2011) |
| "Chemotherapy of glioblastoma is largely ineffective as the blood-brain barrier (BBB) prevents entry of most anticancer agents into the brain." | ( Bernreuther, C; Gelperina, S; Glatzel, M; Khalansky, AS; Kreuter, J; Maksimenko, O; Wohlfart, S, 2011) |
| "Glioblastoma is the most malignant form of adult brain tumor and is associated with a dismal prognosis." | ( Cheng, J; Huang, H; Lin, H; Liu, B; Xiong, W; Zhang, W; Zhang, X; Zhang, Y, 2011) |
| "Glioblastomas are highly lethal cancers for which conventional therapies provide only palliation." | ( Flavahan, WA; Heddleston, JM; Hitomi, M; Hjelmeland, AB; Kim, Y; Minhas, S; Rich, JN; Venere, M; Yang, K, 2011) |
| "Delineation of glioblastoma is complex." | ( Guillevin, R; Noël, G, 2011) |
| "Glioblastoma is the most malignant type of brain tumor." | ( Fukushima, T; Kataoka, H; Kawaguchi, M; Takeshima, H; Tanaka, H; Umezawa, K; Yorita, K, 2012) |
| "Glioblastoma is a highly malignant brain tumor that relentlessly defies therapy." | ( Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA, 2011) |
| "In most cases, glioblastoma are characterized by a constitutive activation of NF-κB." | ( Agostinis, P; Coupienne, I; Fettweis, G; Piette, J; Rubio, N, 2011) |
| "Glioblastomas are invasive tumors with poor prognosis despite current therapies." | ( Agostino, NR; DiDomenico, JD; Jane, EP; Pollack, IF; Premkumar, DR, 2013) |
| "Glioblastoma is an aggressive primary brain tumor with a 5-year survival rate of less than 5%." | ( Greenwood, JA; La Du, J; Lal, S; Tanguay, RL, 2012) |
| "Glioblastoma is a deadly cancer with intrinsic chemoresistance." | ( Anelli, V; Bassi, R; Brioschi, L; Campanella, R; Caroli, M; De Zen, F; Gaini, SM; Giussani, P; Riboni, L; Riccitelli, E; Viani, P, 2012) |
| "Glioblastoma is universally fatal because of its propensity for rapid recurrence due to highly migratory tumor cells." | ( Adamson, DC; Bigner, D; Bortoff, K; Di, C; Duncan, C; Fu, J; Gregory, S; Killela, P; Lin, N; McLendon, R; Truszkowski, P, 2012) |
| "Glioblastomas are known to be highly chemoresistant, but HDAC inhibitors (HDACi) have been shown to be of therapeutic relevance for this aggressive tumor type." | ( Bajbouj, K; Hartig, R; Mawrin, C; Roessner, A; Schneider-Stock, R; Schulze-Luehrmann, J; Wilisch-Neumann, A, 2012) |
| "Glioblastoma is the most common and most malignant primary brain tumor in adults." | ( Hedderich, J; Mehdorn, HM; Nabavi, A; Stark, AM; van de Bergh, J, 2012) |
| "Glioblastoma is a devastating, incurable disease with few known prognostic factors." | ( Berger, MS; Brem, S; Browning, JE; Buckner, JC; Chang, SM; Decker, PA; Egan, KM; Fridley, BL; Hansen, HM; Jenkins, RB; Kosel, ML; Lachance, DH; Madden, MH; McCoy, LS; Nabors, LB; O'Neill, BP; Olson, JJ; Patoka, JS; Prados, MD; Rice, T; Smirnov, I; Thompson, RC; Tihan, T; Wiemels, JL; Wiencke, JK; Wrensch, MR; Xiao, Y, 2012) |
| "Glioblastoma is the most aggressive brain tumour of the adult with a high rate of mortality." | ( Baruzzi, A; Cerasoli, S; de Biase, D; Marucci, G; Morandi, L; Pession, A; Taccioli, C; Visani, M, 2012) |
| "Pediatric glioblastoma is a malignant disease with an extremely poor clinical outcome." | ( Chen, SH; Cheng, CC; Chiu, TH; Huang, YT; Lai, PC; Yang, SH, 2012) |
| "The fatal nature of glioblastoma is caused by tumor-initiating glioblastoma cells." | ( Altaner, C; Altanerova, V, 2012) |
| "Most patients with glioblastoma are older than 60 years, but treatment guidelines are based on trials in patients aged only up to 70 years." | ( Abacioglu, U; Frappaz, D; Grønberg, BH; Hegi, ME; Henriksson, R; Lhermitte, B; Malmström, A; Marosi, C; Rosell, J; Schultz, H; Stupp, R; Tavelin, B, 2012) |
| "Glioblastoma is one of the most lethal and common malignant human brain tumors, with aggressive proliferation and highly invasive properties." | ( Chang, KC; Jeong, JJ; Kim, HJ; Lee, JH, 2012) |
| "Glioblastoma is one of the most aggressive tumors with poor prognosis." | ( Akiyama, T; Ao-Kondo, H; Koyama-Nasu, R; Kozuka-Hata, H; Nasu-Nishimura, Y; Oyama, M; Tsumoto, K, 2012) |
| "Glioblastomas are highly aggressive brain tumors of adults with poor clinical outcome." | ( Balabanov, S; Bokemeyer, C; Braig, M; Hagel, C; Hauber, J; Lamszus, K; Pällmann, N; Preukschas, M; Schulte, A; Sievert, H; Weber, K, 2012) |
| "Glioblastoma is a brain tumor with poor prognosis in the therapy of which operation, postoperative temozolomide sensitized radiochemotherapy followed by temozolomide monotherapy offer the best chances." | ( Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R, 2012) |
| "Glioblastoma is the most common and most aggressive form of malignant glioma and is very difficult to treat." | ( Nakabayashi, H; Shimizu, K, 2012) |
| "Glioblastoma is the most common and most lethal form of brain tumor in human." | ( Chen, F; Kang, D; Li, X; Song, Y; Wang, J; Yang, CJ; Zhang, W; Zhu, M; Zhu, Z; Zou, Y, 2012) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | ( Caporello, P; Enrici, RM; Minniti, G; Scaringi, C, 2012) |
| "Glioblastoma is a rapidly evolving high-grade astrocytoma that is distinguished pathologically from lower grade gliomas by the presence of necrosis and microvascular hyperplasia." | ( Calvo, GF; Martínez-González, A; Pérez Romasanta, LA; Pérez-García, VM, 2012) |
| "Glioblastomas are very difficult tumors to treat because they are highly invasive and disseminate within the normal brain, resulting in newly growing tumors." | ( Akino, T; Bielenberg, DR; Coma, S; Italiano, JE; Klagsbrun, M; König, C; Mammoto, A; Nakayama, H; Sandlund, J; Shimizu, A; Wang, P, 2013) |
| "Glioblastoma is the most common form of primary adult brain tumors." | ( Adrados, I; Allison, J; Arauz, R; Desprez, PY; Fukuyo, Y; Kawamura, R; Khan, S; Limbad, C; McAllister, SD; Moore, DH; Murase, R; Nguyen, D; Pakdel, A; Singer, E; Soroceanu, L; Yount, GL, 2013) |
| "Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis." | ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Florio, T; Marubbi, D; Pattarozzi, A, 2013) |
| "We here show that glioblastomas are capable to downregulate MGMT expression independently of promoter methylation by elongation of the 3'-UTR of the mRNA, rendering the alternatively polyadenylated transcript susceptible to miRNA-mediated suppression." | ( Egensperger, R; Hinske, LC; Hoefig, K; Kreth, FW; Kreth, S; Limbeck, E; Schütz, SV; Thon, N, 2013) |
| "Glioblastoma is refractory to conventional therapies." | ( Cheng, Z; Gong, Y; Knapp, S; Lu, K; Lu, X; Ma, Y; Muller, S; Pierce, LA; Thompson, RC; Wang, J, 2013) |
| "Glioblastoma is one of the intractable cancers and is highly resistant to ionizing radiation." | ( Asanuma, T; Inanami, O; Kino, J; Kubota, N; Kuwabara, M; Meike, S; Nagane, M; Yamamori, T; Yasui, H, 2013) |
| "Recurrent glioblastoma is nearly always fatal, with median survival rates of approximately 12-14 months." | ( Banfi, R; Cecchi, M; Ceroti, M; Vaiani, M, 2013) |
| "Glioblastoma is a notoriously difficult tumor to treat because of its relative sanctuary in the brain and infiltrative behavior." | ( Alkins, RD; Brodersen, PM; Hynynen, K; Sodhi, RN, 2013) |
| "Glioblastoma is the most common malignant primary brain tumour in adults and one of the most lethal of all cancers." | ( Carrasco, MP; Marco, C; Martín-Fernández, M; Ríos, A; Ríos-Marco, P; Soria-Bretones, I, 2013) |
| "Glioblastoma are one of the mostly vascularized tumors and are histologically characterized by abundant endothelial cell proliferation." | ( Batchelor, TT; de Groot, J; Reardon, DA, 2013) |
| "Glioblastoma is the most common and lethal cancer of the central nervous system." | ( Bai, Y; Bao, ZS; Chen, Y; Wang, LJ; Yan, ZH; Zhang, QG; Zhang, W, 2013) |
| "Glioblastoma is the most common type of primary brain tumors." | ( Chen, F; Fang, J; Guo, Y; Qu, Q; Yan, K; Zhou, M, 2013) |
| "Glioblastomas are the most frequent and aggressive intracranial neoplasms in humans, and despite advances and the introduction of the alkylating agent temozolomide in therapy have improved patient survival, resistance mechanisms limit benefits." | ( Caroli, M; Condomitti, G; Di Vito, C; Galli, R; Giussani, P; Riboni, L; Riccitelli, E; Tringali, C; Viani, P, 2013) |
| "Glioblastoma is the most frequent brain tumor of glial origin in adults." | ( Bachem, MG; Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR; Zhou, S, 2013) |
| "Glioblastoma is the most lethal brain cancer." | ( Li, C; Li, X; Liu, X; Yan, B; Zhang, Q; Zhou, H, 2013) |
| "Glioblastoma is a highly malignant, invariably fatal brain tumor for which effective pharmacotherapy remains an unmet medical need." | ( Brüstle, O; Fimmers, R; Glas, M; Gogolok, S; Höfer, H; Keller, M; Klaas, L; Koch, P; Leinhaas, A; Normann, S; Pietsch, T; Pincus, DW; Reinartz, R; Scheffler, B; Schelle, R; Simon, M; Steindler, DA; Trageser, D; Waha, A; Wieland, A; Yachnis, AT, 2013) |
| "Glioblastoma is a highly vascularized brain tumor, and antiangiogenic therapy improves its progression-free survival." | ( Jiang, A; Jiang, E; Kieran, MW; Mammoto, A; Mammoto, T; Panigrahy, D, 2013) |
| "Glioblastomas are the most aggressive forms of primary brain tumors due to their tendency to invade surrounding healthy brain tissues, rendering them largely incurable." | ( Ding, T; Fu, L; Gu, F; Jiang, W; Li, W; Li, Z; Liu, X; Ma, Y; Sun, K; Tian, C; Ying, G; Zhou, Y, 2013) |
| "Glioblastoma is the most aggressive and common type of malignant brain tumor in humans, with a median survival of 15 months." | ( Kaur, B; Meisen, WH; Racoma, IO; Wang, QE; Wani, AA, 2013) |
| "Glioblastoma is the most aggressive cerebral gliomas." | ( Feng, J; Leng, X; Li, J; Li, W; Lian, S; Wang, C; Wang, H; Zhang, X, 2014) |
| "Glioblastoma is a highly aggressive malignant disease with notable resistance to chemotherapy." | ( Han, G; Hu, X; Li, Y; Liu, J; Wang, L; Yue, Z; Zhao, R; Zhao, W; Zhou, X, 2013) |
| "Glioblastoma is the most prevalent and malignant primary brain tumor in adults, and its response to current therapies is limited." | ( Ji, H; Lu, Z, 2013) |
| "Glioblastomas are the most aggressive primary brain tumors and their heterogeneity and complexity often renders them non responsive to various conventional treatments." | ( Kaur, G; Mishra, R, 2013) |
| "Glioblastoma is one of the most lethal and prevalent malignant human brain tumors, with aggressive proliferation and highly invasive properties." | ( Chang, KC; Eun, SY; Joo, YN; Kim, HJ; Lee, JH; Park, SW, 2014) |
| "Radiosurgery for glioblastoma is limited to the development of resistance, allowing tumor cells to survive and initiate tumor recurrence." | ( Chen, Z; Hu, Z; Tu, J, 2013) |
| "Human glioblastoma is highly resistant to chemotherapy with temozolomide." | ( Chung, H; Jo, S; Kim, IC; Kim, S; Kim, TU; Lee, H; Yim, JH, 2013) |
| "Epithelioid glioblastoma is among the rarest variants of glioblastoma and is not formally recognized in the World Health Organization classification; it is composed of monotonous, discohesive sheets of small, round cells with eccentric nuclei and eosinophilic cytoplasm devoid of cytoplasmic stellate processes, showing the retention of nuclear staining of INI-1 protein." | ( Hirato, J; Ikota, H; Kurihara, H; Nagaishi, M; Nakazato, Y; Nobusawa, S; Ogawa, A; Okura, N; Yokoo, H, 2014) |
| "Glioblastomas are lethal tumors characterized by malignant proliferation and recurrence promoted partly by glioblastoma stem cells (GSCs)." | ( Bai, YF; Chen, J; Guo, HB; Liao, HZ; Liu, TZ; Qiu, SC; Wang, X; Yan, XH; Yang, YQ; Zhang, SZ, 2014) |
| "Human glioblastoma is the most frequent and aggressive type of brain tumors." | ( Baklaushev, VP; Chekhonin, VP; Grinenko, NP; Gubskiy, IL; Gurina, OI; Kabanov, AV; Kardashova, KSh; Khalansky, AS; Melnikov, PA; Nukolova, NN; Yusubalieva, GM, 2015) |
| "Glioblastoma is known as one of the most aggressive human cancers." | ( Akbarzadeh, A; Alavi, SE; Ebrahimi Shahmabadi, H; Eslamifar, A; Koohi Moftakhari Esfahani, M; Mohammadi Anaraki, G; Movahedi, F, 2014) |
| "Glioblastoma is the most common brain tumor in adults." | ( Depping, R; Jelkmann, W; Sun, W, 2014) |
| "Glioblastoma is the most common malignant primary brain tumor." | ( Boots-Sprenger, SH; Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Tannous, BA; Teng, J; Tops, B; Vandertop, WP; Wesseling, P; Wurdinger, T, 2014) |
| "Glioblastoma is the most common malignant brain tumor in adults and characterized by a poor prognosis." | ( Deenen, R; Florea, AM; Frei, K; Happold, C; Lamszus, K; Reifenberger, G; Roth, P; Silginer, M; Weller, M, 2014) |
| "Glioblastoma is an invasive tumor of the central nervous system." | ( Babaei, E; Bilia, AR; Isacchi, B; Marra, F; Mowla, SJ; Najafi, F; Sadeghizadeh, M; Tahmasebi Mirgani, M, 2014) |
| "Glioblastoma is the most common and most aggressive malignant primary brain tumor in humans, accounting for 52 % of all functional tissue brain tumor cases and 20 % of all intracranial tumors." | ( Cheng, T; Gao, Y; Guo, W; Li, S; Liu, Y; Ma, W; Zhou, G, 2014) |
| "Glioblastoma are the most frequent and malignant human brain tumors, having a very poor prognosis." | ( Alt, A; Debatin, KM; Fichtner, I; Friesen, C; Hilger, R; Hormann, I; Miltner, E; Roscher, M, 2014) |
| "Glioblastoma is an aggressive tumor that occurs in both adult and pediatric patients and is known for its invasive quality and high rate of recurrence." | ( Keating, AK; Knubel, KH; Nelson, S; Pernu, BM; Pierce, AM; Sufit, A, 2014) |
| "Glioblastoma is the most malignant and lethal form of astrocytoma, with patients having a median survival time of approximately 15 months with current therapeutic modalities." | ( Al-Abed, Y; Didier, S; Issaivanan, M; Miller, IS; Murray, DW; Ruggieri, R; Symons, M; Turner, TH, 2014) |
| "Glioblastoma is one of the most aggressive brain tumors with high morbidity and mortality." | ( Han, XJ; Jiang, LP; Lai, QN; Wan, YY; Wang, JB; Wei, YF; Xin, HB; Yang, ZJ; Zhang, JF, 2014) |
| "Glioblastomas are highly malignant brain tumours." | ( Becker, S; Buzug, TM; Mang, A; Schuetz, TA; Toma, A, 2014) |
| "Glioblastoma is one of the most aggressive human cancers with poor prognosis, and therefore a critical need exists for novel therapeutic strategies for management of glioblastoma patients." | ( Chen, Y; Cheng, L; Huang, C; Lan, J; Lei, Y; Li, J; Li, Y; Liu, R; Nice, EC; Wang, K; Wei, Y; Xiang, R; Xie, N; Yuan, K; Zhang, T; Zou, L, 2014) |
| "Glioblastoma is the most prevalent primary brain tumor and is essentially universally fatal within 2 years of diagnosis." | ( Bai, Y; Flavahan, W; Lathia, JD; Mattson, MP; Rich, JN; Zhang, P, 2014) |
| "Almost all glioblastomas are intrinsically resistant to chemotherapeutic temozolomide (TMZ) or develop resistance during treatment." | ( Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Raktoe, RS; Vandertop, WP; Wesseling, P; Wurdinger, T, 2014) |
| "Glioblastoma is the most common and aggressive primary brain tumor in adults, with a poor prognosis because of its resistance to radiotherapy and chemotherapy." | ( Camacho, L; Guerrero, PA; Marchetti, D; Yin, W, 2015) |
| "Glioblastoma is a highly lethal cancer." | ( Nakano, I, 2014) |
| "Grade IV glioma (glioblastoma) is one of the most common brain/central nervous system cancers." | ( Hay, JW; Messali, A; Villacorta, R, 2014) |
| "Glioblastoma is the most aggressive primary brain tumor in adults." | ( Chinot, O; Delattre, JY; Hoang-Xuan, K; Idbaih, A; Loundou, A; Sanson, M; Tabouret, E, 2014) |
| "Grade IV glioblastoma is characterized by increased kinase activity of epidermal growth factor receptor (EGFR); however, EGFR kinase inhibitors have failed to improve survival in individuals with this cancer because resistance to these drugs often develops." | ( Aldape, K; Berens, ME; Carrera-Silva, EA; Dietrich, JD; Errasti, AE; Ghosh, S; Gibbs, D; Hulme, C; Kusne, Y; Loftus, JC; Lu, Z; Mandell, EK; Perry, AS; Rothlin, CV; Rushing, EJ; Sanai, N; Yang, W, 2014) |
| "Glioblastoma is a highly aggressive, common brain tumor with poor prognosis." | ( Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA, 2015) |
| "Glioblastoma is the most common primary malignant brain tumor, but despite multimodal treatment with surgery, radiotherapy, and temozolomide chemotherapy, the prognosis is poor, with a median survival of 16 to 19 months and poor quality of life throughout the disease course." | ( Brennan, CW; DeAngelis, LM; Omuro, AM; Thomas, AA, 2014) |
| "Glioblastoma is an aggressive tumor with heterogeneous molecular features and complex host interactions, many of which are amenable to therapeutic intervention." | ( Brennan, CW; DeAngelis, LM; Omuro, AM; Thomas, AA, 2014) |
| "Glioblastoma is the most common and most fatal primary malignant brain tumor in adults." | ( Folkerth, RD; Milner, DA; Ramkissoon, SH; Solomon, IH, 2014) |
| "Glioblastoma is an aggressive malignancy, which is notorious for its poor prognosis." | ( Fei, Z; He, X; Liu, W; Wang, Y, 2015) |
| "Glioblastoma is the most common malignant brain tumor in adults and carries a particularly poor prognosis." | ( Barnholtz-Sloan, JS; Bauchet, L; Woehrer, A, 2014) |
| "Glioblastoma is an aggressive malignancy, which is associated with poor prognosis." | ( Guo, H; Guo, M; Wang, Y; Yang, L, 2015) |
| "Glioblastoma is the most frequent primary brain tumor in adults." | ( Baeza-Kallee, N; Beclin, C; Carré, M; Colin, C; Denicolaï, E; Figarella-Branger, D; Jiglaire, CJ; Mercurio, S; Tchoghandjian, A, 2014) |
| "Glioblastomas are highly aggressive adult brain tumors with poor clinical outcome." | ( Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S, 2014) |
| "Glioblastoma is the most fatal type of brain tumor, requiring a better chemotherapy regime to prolong the survival of the patient." | ( Mohanta, GP; Mohanty, AK, 2015) |
| "Glioblastoma is the most common adult malignant primary brain tumor." | ( Ahluwalia, MS; Peereboom, DM; Venur, VA, 2015) |
| "Glioblastoma is the most aggressive primary brain tumor, and is associated with a very poor prognosis." | ( Alder, JE; Boissinot, M; Droop, A; Hayes, J; Hughes, TA; Lawler, SE; Shaw, L; Short, SC; Thygesen, H; Tumilson, C; Westhead, D, 2015) |
| "Glioblastoma is a rapidly infiltrating tumor that consistently rematerializes despite various forms of aggressive treatment." | ( Cohen-Gadol, AA; Harvey, KA; Pollok, K; Saaddatzadeh, MR; Siddiqui, RA; Wang, H; Xu, Z, 2015) |
| "Glioblastoma is a devastating primary brain tumor resistant to conventional therapies." | ( Battastini, AM; Bishop, AJR; Braganhol, E; Bristot, IJ; Figueiró, F; Forcelini, CM; Gelain, DP; Klafke, K; Moreira, JCF; Morrone, M; Paludo, FJ; Terra, SR; Zanotto-Filho, A, 2015) |
| "Glioblastoma is the most common brain tumor and is characterized with robust invasion and migration potential resulting in poor prognosis." | ( Li, JC; Rao, W; Shi, ZX; Si, JW; Wang, H; Wang, ND; Wang, ZR; Zhao, J, 2015) |
| "Glioblastoma is the most common and most aggressive primary brain malignancy." | ( Chang, MY; Chou, YC; Chung, JG; Harnod, T; Hung, CH; Lee, HT; Shen, CC; Wang, MJ, 2015) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | ( Benoit, JP; Danhier, F; Lagarce, F; Lemaire, L; Messaoudi, K, 2015) |
| "Glioblastoma is the most malignant brain tumor, exhibiting remarkable resistance to treatment." | ( Correia, S; Costa, BM; Costa, S; Gonçalves, CS; Gonçalves, T; Lopes, JM; Oliveira, AI; Pinto, AA; Pinto, L; Pojo, M; Reis, RM; Rocha, M; Rodrigues, AJ; Sousa, N; Xavier-Magalhães, A, 2015) |
| "Glioblastoma is the most common, aggressive and highly malignant type of primary brain tumor." | ( Liao, A; Lin, KW; Qutub, AA, 2015) |
| "Multifocal glioblastoma is an uncommon and refractory subtype of high-grade glioma since the burden of masses could not be eliminated simply by operation, and it is getting even harder to control if some deep structures, like thalamus and pineal region, are involved." | ( Gao, Z; Hao, S; Liu, Y; Yu, L, 2015) |
| "Glioblastomas are progressive brain tumors with devastating proliferative and invasive characteristics." | ( Barszczyk, A; Chen, WL; Deurloo, M; Feng, ZP; Liu, B; Rutka, JT; Sun, HS; Turlova, E; Yang, BB, 2015) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | ( Danhier, F; des Rieux, A; Fourniols, T; Leprince, JG; Préat, V; Randolph, LD; Staub, A; Vanvarenberg, K, 2015) |
| "Glioblastomas are differentially sensitive to Delta24-RGD." | ( Berghauser Pont, LM; de Vrij, J; Dirven, CM; Kaufmann, JK; Kleijn, A; Kloezeman, JJ; Lamfers, ML; Leenstra, S; van den Bossche, W, 2015) |
| "Glioblastomas are invasive therapy resistant brain tumors with extremely poor prognosis." | ( Behnan, J; Fjerdingstad, HB; Glover, JC; Grieg, Z; Joel, M; Langmoen, IA; Mikkelsen, B; Mughal, AA; Murrell, W; Palmero, S; Sandberg, CJ; Stangeland, B, 2015) |
| "Glioblastoma are among the most angiogenic tumors." | ( Burghardt, I; Frei, K; Krishnan, S; Szabo, E; Tabatabai, G; Weller, M, 2015) |
| "Glioblastoma is the deadliest brain tumor in humans." | ( Chakrabarti, M; Ray, SK, 2015) |
| "Glioblastoma is the most common intracranial malignancy that constitutes about 50 % of all gliomas." | ( Eder, K; Kalman, B, 2015) |
| "Glioblastoma is the most aggressive primary brain tumor with hypoxia-associated morphologic features including pseudopalisading necrosis and endothelial hyperplasia." | ( Chi, SG; Chung, YG; Kang, SH; Park, DH; Park, KJ; Yu, MO, 2015) |
| "Glioblastoma is the most aggressive primary brain malignancy, and the efficacy of multimodality treatments remains unsatisfactory." | ( Chang, MY; Chou, YC; Chung, JG; Harnod, T; Hung, CH; Lee, HT; Liu, HC; Wang, MJ; Yu, FS, 2015) |
| "Epileptogenic glioblastomas are thought to convey a favorable prognosis, either due to early diagnosis or potential antitumor effects of antiepileptic drugs." | ( Berendsen, S; Bours, V; Broekman, ML; Kauw, F; Kroonen, J; Poulet, C; Robe, PA; Seute, T; Snijders, TJ; Spliet, WG; Varkila, M; Willems, M, 2016) |
| "Glioblastomas are the most common brain tumors in humans." | ( Carpinelli, G; Castigli, E; Conte, C; Degrassi, F; Di Bari, M; Fiore, M; Iorio, E; Ricordy, R; Sciaccaluga, M; Tata, AM; Tombolillo, V, 2015) |
| "Glioblastoma is the most lethal brain tumor." | ( Chakrabarti, M; Ray, SK, 2015) |
| "Glioblastoma is the most frequent primary brain tumor in adults." | ( Bâ, M; Bruce, JN; Canoll, P; Halatsch, ME; Karpel-Massler, G; Shu, C; Siegelin, MD; Westhoff, MA, 2015) |
| "Glioblastoma is the most common and aggressive form of intrinsic brain tumor." | ( Bunse, L; Burghardt, I; Gramatzki, D; Hao, N; Leske, H; Platten, M; Roth, P; Rushing, EJ; Silginer, M; Weller, M, 2016) |
| "Glioblastoma is the most common tumor of the central nervous system and one of the hardest tumors to treat." | ( Borges, KS; Brassesco, MS; de Oliveira, JC; dos Santos, MH; Ionta, M; Pezuk, JA; Sales, L; Scrideli, CA; Tone, LG, 2015) |
| "Glioblastoma is the most malignant primary brain tumor and is highly infiltrative." | ( Ang, BT; Chong, YK; Holbrook, JD; Koh, GR; Koh, LW; Kon, OL; Lim, GG; Lim, KL; Nadarajah, M; Ng, I; Ng, WH; Sandanaraj, E; Tan, MS; Tan, NS; Tang, C; Thangaveloo, M; Toh, TB, 2016) |
| "Glioblastoma is the most common and lethal type of primary brain tumor." | ( Gao, X; Li, X; Li, Z; Liang, G; Luo, L; Song, Z; Su, J; Wang, X; Xie, P; Zhu, T, 2015) |
| "Glioblastoma is the deadliest brain tumor in humans." | ( Chakrabarti, M; Ray, SK, 2016) |
| "Glioblastomas are highly aggressive tumors that contain treatment resistant stem-like cells." | ( Chu, Q; Eberhart, CG; Kahlert, UD; Kaur, H; Liu, Y; Maitani, K; Miyahara, H; Natsumeda, M; Zhang, H, 2016) |
| "Glioblastoma is the most common and the most lethal primary brain tumor in adults." | ( , 2016) |
| "Glioblastoma is the most common malignant brain tumor accounting for more than 54 % of all gliomas." | ( Aithal, MG; Chand, AK; Narayanappa, R; Rout, P, 2016) |
| "Glioblastoma is the most devastating primary malignancy of the central nervous system in adults." | ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "Glioblastoma is the most common and aggressive primary brain malignancy." | ( Chang, MY; Chang, SJ; Chou, YC; Chung, JG; Harnod, T; Hung, CH; Lee, HT; Liu, HC; Shen, CC; Wang, MJ, 2017) |
| "Glioblastoma is a malignant human cancer that confers a dismal prognosis." | ( Liang, Z; Long, L; Wang, L; Wang, W, 2015) |
| "Glioblastoma is almost always incurable and most older patients survive less than 6 months." | ( Mohile, NA, 2016) |
| "GBM (Glioblastoma) is the most malignant human brain tumor with median survival of one year." | ( Lal, N; Luthra, PM, 2016) |
| "Glioblastoma is one of the most malignant primary tumors, and the prognosis for glioblastoma patients remains poor." | ( Ahn, KS; Choi, M; Ha, IJ; Kim, SH; Lee, JH; Lee, SG; Lim, SL; Park, D; Park, SY; Yun, M, 2016) |
| "Glioblastoma is an aggressive, invasive tumor of the central nervous system (CNS)." | ( Behera, P; Chiocca, EA; Cho, CF; Lawler, SE; Nowicki, MO; Speranza, MC, 2016) |
| "Glioblastoma is the most common and deadly primary brain tumor in adults." | ( Feng, F; Ling, Z; Sun, C; Wang, L; Wang, S; Wu, B; Xia, L; Yu, Y, 2016) |
| "Glioblastoma is a unique model of non-metastasising disease that kills the vast majority of patients through local growth, despite surgery and local irradiation." | ( Giatromanolaki, A; Koukourakis, MI; Mitrakas, AG, 2016) |
| "Glioblastomas are extremely aggressive brain tumors with highly invasive properties." | ( Ang, BT; Chong, YK; Gauthier, NC; Guetta-Terrier, C; Krishnasamy, A; Ladoux, B; Monzo, P; Ng, WH; Sathe, SR; Sheetz, MP; Tang, C; Yim, EK, 2016) |
| "Glioblastoma is an uncommon and aggressive primary brain tumor with incidence of 3 per 100,000 annually." | ( Golzy, N; Pouratian, N; Sharim, J; Tashjian, R, 2016) |
| "Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14." | ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016) |
| "Glioblastoma is an invasive primary brain malignancy that typically infiltrates the surrounding tissue with malignant cells." | ( Canoll, P; Chow, DS; Filippi, CG; Grinband, J; Hillman, EM; Horenstein, CI; Lignelli, A, 2016) |
| "Glioblastoma is the most common and most aggressive primary brain tumour." | ( Alikhanyan, K; Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M; Dai, C; Donnola, S; Gorlia, T; Hambardzumyan, D; Hentschel, B; Holland, EC; Hosni-Ahmed, A; Jones, TS; Ozawa, T; Pattwell, SS; Pitter, KL; Schlegel, U; Stupp, R; Tamagno, I; Weller, M, 2016) |
| "Recurrent glioblastoma is associated with a poor overall survival." | ( Aerts, JL; Benteyn, D; De Keersmaecker, B; Du Four, S; Duerinck, J; Maenhout, SK; Neyns, B; Thielemans, K, 2016) |
| "Glioblastoma is the most frequent malignant brain tumor." | ( Alonso, MM; Fueyo, J; García-Garzón, A; Gomez-Manzano, C; Gonzalez-Huarriz, M; Jiang, H; Lang, FF; Martinez de Irujo, JJ; Xipell, E, 2016) |
| "Glioblastoma is the most frequent and malignant brain tumor." | ( Battastini, AM; Coelho, BP; de Quadros, AH; Gaelzer, MM; Gonçalves, CA; Guerra, MC; Guma, FC; Hoppe, JB; Salbego, CG; Setton-Avruj, P; Terra, SR; Usach, V, 2016) |
| "Glioblastoma is characterized by an aggressive and aberrant vascular network that promotes tumor progression and hinders effective treatment; the median survival is 16 mo despite standard-of-care therapies." | ( Behling, K; Gutin, PH; López Puebla, JC; Maguire, WF; McDevitt, MR; O'Donoghue, J; Ruggiero, A; Scheinberg, DA; Sprinkle, SR, 2016) |
| "Glioblastoma is an aggressive brain cancer requiring improved treatments." | ( Greenwood, JA; Punnoose, A; Tanguay, RL; Wehmas, LC, 2016) |
| "Glioblastoma is associated with poor prognosis with a median survival of one year." | ( Andersson, U; Antti, H; Björkblom, B; Johannesen, TB; Jonsson, P; Langseth, H; Melin, B; Mörén, L; Wibom, C, 2016) |
| "Glioblastoma is a malignant brain tumor originating in the central nervous system." | ( Chen, Z; Gao, Z; Lai, X; Mao, G; Qu, J; Zhang, L; Zhu, J; Zhu, X, 2016) |
| "Glioblastoma is one of the most aggressive solid tumors, and, despite treatment options such as surgery, radiation, and chemotherapy, its prognosis remains grim." | ( Chiocca, EA; Lim, M; Weller, M, 2016) |
| "Glioblastoma is the most common malignant brain tumor in adults." | ( Anota, A; Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dabakuyo, S; Dalban, C; Ducray, F; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Paquette, B; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I; Vernerey, D, 2016) |
| "Glioblastoma is a fatal and incurable cancer with the hyper-activated mTOR pathway." | ( Deng, H; Li, J; Liu, X; Luo, M; Tang, H; Wang, G, 2016) |
| "Glioblastoma is the most common and malignant brain tumor in humans." | ( Chakrabarti, M; Klionsky, DJ; Ray, SK, 2016) |
| "Glioblastoma is the most malignant form of brain tumor." | ( Choi, E; Han, J; Lee, D; Lee, M; Oh, J; Rhim, T; Tan, X, 2017) |
| "Glioblastomas are highly invasive and aggressive primary brain tumors." | ( Davidoff, AM; Pfeffer, LM; Wang, R, 2016) |
| "Glioblastoma is the most malignant tumor of the central nervous system and still lacks effective treatment." | ( Berghauser Pont, LM; Besselink, NJ; Caljouw, E; Dekker, LJ; Dubbink, HJ; Hoogstraat, M; Joore, J; Kloezeman, J; Lamfers, ML; Leenstra, S; Luider, TM; Martens, JW; Pierson, T; Sleijfer, S; Spoor, JK; van der Kaaij, M; Venkatesan, S; Zeneyedpour, L, 2016) |
| "Glioblastoma is the most malignant primary brain tumor, with a median survival of less than 2 years." | ( Clark, PA; Eliceiri, KW; Kuo, JS; Pointer, KB; Robertson, GA; Salamat, MS, 2017) |
| "Glioblastoma is a malignant tumor of astrocytic origin that is highly invasive, proliferative and angiogenic." | ( Amaral, R; da Fonseca, AC; Garcia, C; Geraldo, LH; Lima, FR; Matias, D, 2016) |
| "Pediatric glioblastoma is one of the most common and most deadly brain tumors in childhood." | ( , 2016) |
| "Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%." | ( Hirose, Y; Ohba, S, 2016) |
| "Glioblastoma is one of the most vascular brain tumour and highly resistant to current therapy." | ( Fang, S; Liu, B; Liu, Y; Sun, Q, 2016) |
| "Glioblastoma is an aggressive brain tumor that requires multidisciplinary treatment including adjuvant radiotherapy, chemotherapy, and adjunct corticosteroids." | ( Hatakeyama, S; Ikeda, T; Morisawa, Y; Norizuki, M; Okabe, T; Onishi, T; Sasahara, T; Suzuki, J; Toshima, M; Yokota, H, 2017) |
| "Glioblastoma is an aggressive and incurable primary brain tumor." | ( Mirzaei, R; Sarkar, S; Yong, VW, 2017) |
| "Glioblastoma is a high-grade cerebral tumor with local recurrence and poor outcome." | ( Duhamel, A; Leroux, B; Leroy, HA; Maurage, CA; Mordon, S; Reyns, N; Vermandel, M; Vignion-Dewalle, AS, 2017) |
| "Glioblastoma is an aggressive tumor that is associated with distinctive infiltrating microglia/macrophages populations." | ( Chen, J; Chen, X; Ji, M; Jia, J; Jiang, J; Jin, J; Lai, F; Li, W; Xue, N; Yang, H; Zhang, J; Zhang, M; Zhou, Q, 2017) |
| "Glioblastoma is the most common malignant brain tumor." | ( Assad Kahn, S; Aulestia, FJ; Cheshier, SH; Chneiweiss, H; Daubeuf, F; Dong, J; Dubois, LG; El-Habr, EA; Frossard, N; Haiech, J; Junier, MP; Kilhoffer, MC; Leclerc, C; Moreau, M; Néant, I; Tounsi, N; Zeniou, M, 2017) |
| "Glioblastoma is a common malignant brain tumor and it is refractory to therapy because it usually contains a mixture of cell types." | ( Chan, TM; Deng, Y; Hu, X; Liu, PC; Lu, G; Poon, WS; Su, XW; Wang, CD; Zhou, JY, 2017) |
| "Glioblastoma is the most aggressive manifestation of malignant gliomas and considered to be among the deadliest forms of human cancers." | ( Chen, L; Fan, J; Li, Y; Liu, Z; Wang, J; Xu, R, 2017) |
| "Glioblastoma is a kind of malignant gliomas that is almost impossible to cure due to the poor drug transportation across the blood-brain barrier and the existence of glioma stem cells." | ( Li, X; Tang, H; Wang, Y; Xu, H; Yan, H; Ying, X, 2017) |
| "Glioblastoma is the most frequent and most malignant brain tumor with the patients having a median survival of only 14." | ( Aaberg-Jessen, C; Halle, B; Jensen, SS; Kristensen, BW; Petterson, SA, 2017) |
| "Glioblastoma is the most common and deadliest primary brain tumor for humans." | ( Belluco, S; Berger, F; Bonnefont-Rebeix, C; Carozzo, C; Chuzel, T; Dreyfus, M; Khoshnevis, M; Leveneur, O; Pillet-Michelland, E; Ponce, F; Roger, T, 2017) |
| "Glioblastoma is associated with a poor prognosis in the elderly." | ( Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C, 2017) |
| "Optic nerve glioblastoma is a rare entity that usually presents with rapidly progressive vision loss, which eventually results in blindness and, ultimately, death." | ( Beatriz Lopes, M; Caruso, JP; Chen, CJ; Ding, D; Hays, MA; Mastorakos, P; Shaffrey, ME; Taylor, DG, 2018) |
| "Glioblastoma is the most common and most malignant primary brain tumor with a median survival of 15 months." | ( Alexiou, GA; Chousidis, I; Galani, V; Hodaj, E; Kyritsis, AP; Lazari, D; Leonardos, I; Markopoulos, GS; Vartholomatos, E, 2017) |
| "Glioblastomas are characterized by amplification of EGFR." | ( Asuthkar, S; Bach, SE; Guda, MR; Lathia, JD; Sahu, K; Tsung, AJ; Tuszynski, J; Velpula, KK, 2017) |
| "Glioblastoma is one of the most frequent and aggressive brain tumors." | ( Jin, X; Liu, N; Nie, E; Shi, Z; Wu, W; You, Y; Yu, T; Zhang, J; Zhou, X, 2017) |
| "Glioblastoma is the most common and most malignant primary brain tumor with a median survival of 15 months." | ( Alexiou, GA; Galani, V; Hodaj, E; Kyritsis, AP; Lazari, D; Markopoulos, G; Vartholomatos, E, 2017) |
| "Backgroud:Glioblastoma is a kind of highly malignant and aggressive tumours in the central nervous system." | ( Cui, H; Dong, Z; Ke, XX; Lei, Q; Yang, L; Yang, R; Yi, L; Zhu, S, 2017) |
| "Glioblastoma is the most common and lethal brain tumor associated with only 12% median survival rate of patients." | ( Ranjan, A; Srivastava, SK; Wright, S, 2017) |
| "Glioblastoma is the most common type of adult brain tumour and has a median survival after diagnosis of a little more than a year." | ( Gont, A; Hanson, JEL; Kumar, R; Lorimer, IAJ; Perkins, TJ, 2017) |
| "Glioblastoma is one of the most frequent primary brain tumours of the central nervous system, with a poor survival time." | ( Chwalibog, A; Grodzik, M; Jaworski, S; Kutwin, M; Sawosz, E; Strojny, B; Wierzbicki, M, 2017) |
| "Glioblastoma is the most common and most lethal primary brain cancer." | ( Herrera-Rios, D; Hoerbelt, T; Jiang, T; Kahlert, UD; Koch, K; Li, G; Maciaczyk, D; Maciaczyk, J; Marquardt, V; Ouwens, DM; Pauck, D; Picard, D; Remke, M; Steiger, HJ; Zhang, W; Zhao, L, 2017) |
| "Glioblastoma is one of the most malignant and aggressive types of brain tumors." | ( Chaithirayanon, K; Piromkraipak, P; Power, C; Sangpairoj, K; Supavilai, P; Tirakotai, W; Unchern, S; Vivithanaporn, P, 2018) |
| "Glioblastoma is the most common primary tumor of the brain and has few long-term survivors." | ( Daniels, DJ; de Mooij, T; Johnson, AJ; Kaptzan, T; Kumar, R; Parney, IF; Peterson, TE, 2017) |
| "Glioblastoma is the most common primary CNS malignancy and it is becoming more frequently diagnosed in the elderly population." | ( de Moraes, FY; Laperriere, N, 2017) |
| "Glioblastoma is one of the most aggressive malignant primary brain cancer in adults." | ( Cacciatore, I; Ciulla, M; Di Stefano, A; Eusepi, P; Fornasari, E; Marinelli, L; Ozdemir, O; Tatar, A; Turkez, H, 2017) |
| "Glioblastoma is a highly lethal brain cancer that frequently recurs in proximity to the original resection cavity." | ( Chai, JN; Chheda, MG; Diamond, MS; Fernandez, E; Gorman, MJ; Hubert, CG; McKenzie, LD; Prager, BC; Rich, JN; Richner, JM; Shan, C; Shi, PY; Tycksen, E; Wang, X; Zhang, R; Zhu, Z, 2017) |
| "Glioblastoma is the most common and lethal malignant primary brain tumor for which the development of efficacious chemotherapeutic agents remains an urgent need." | ( Cheng, B; Mito, S; Morales, LD; Tsin, A; Zhang, Y, 2017) |
| "Glioblastoma is the most common malignant primary brain tumor, and it is one of the causes of cancer fatality in both adult and pediatric populations." | ( Jiang, Y; Jiao, Y; Li, T; Li, Y; Liu, Y; Wang, D; Wang, Z; Zhao, X, 2017) |
| "Glioblastoma is the most aggressive primary brain tumor that originates from the glial cells in adults." | ( Chen, XJ; Li, J; Lv, LJ; Qiao, HB; Zhang, ZM; Zou, CL, 2017) |
| "Glioblastoma is the most common and aggressive primary brain tumor and has a high mortality in humans." | ( Jing, D; Shen, L; Yu, H; Zhang, Q; Zhao, Y, 2017) |
| "Glioblastoma are highly resistant to radiotherapy and the underlying mechanisms remain unclear." | ( Bache, M; Dehghani, F; Ensminger, S; Ghadban, C; Grabiec, U; Hohmann, T; Vogel, C; Vordermark, D, 2017) |
| "Glioblastoma is a highly aggressive brain tumor." | ( Auslander, N; Ben-Shushan, D; Calderón, M; Eldar-Boock, A; Ferber, S; Grossman, R; Haag, R; Henkin, J; Krivitsky, A; Licha, K; Ofek, P; Ram, Z; Ruppin, E; Satchi-Fainaro, R; Scomparin, A; Sousa-Herves, A; Tiram, G; Vossen, LI; Yeini, E, 2017) |
| "Glioblastoma is a lethal form of brain tumour usually treated by surgical resection followed by radiotherapy and an alkylating chemotherapeutic agent." | ( Cosgrove, L; Fay, MF; Head, RJ; Martin, JH; Rundle-Thiele, D; Y C Fung, K, 2017) |
| "Glioblastoma is the most common and most aggressive form of primary brain tumor in adults and contributes to high social and medical burden as a result of its incurable nature and significant neurologic morbidity." | ( de Groot, JF; Nam, JY, 2017) |
| "Glioblastoma is the most common type of primary brain tumor in adults, with high mortality and morbidity rates." | ( Chen, QX; Liao, JM; Liu, BH; Tan, YQ; Yang, JA; Yang, X; Yuan, FE, 2017) |
| "Here, we show that glioblastoma are excreting large amounts of branched-chain ketoacids (BCKAs), metabolites of branched-chain amino acid (BCAA) catabolism." | ( Becker, HM; Gaupel, AC; Hell, R; Hiller, K; Kneisel, N; Lichter, P; Nonnenmacher, Y; Poschet, G; Radlwimmer, B; Sapcariu, S; Schlotter, M; Seiffert, M; Silva, LS; Wu, Y, 2017) |
| "Glioblastoma is the most common primary brain malignancy and differentiation of true progression from pseudoprogression is clinically important." | ( Choi, SH; Kang, KM; Kim, JH; Lim, WH; Nam, JG; Sohn, CH; Yoo, RE; Yun, TJ, 2017) |
| "Glioblastoma is the most common primary malignant brain tumor diagnosed in the USA and is associated with a poor prognosis." | ( Ahluwalia, MS; Braun, K, 2017) |
| "Glioblastoma is the most frequent primary brain tumor in adults and a highly lethal malignancy with a median survival of about 15 months." | ( Dhruv, H; Ding, Z; Eschbacher, JM; Kloss, J; Loftus, JC; Peng, S; Pirrotte, P; Roos, A; Tran, NL, 2018) |
| "OBJECTIVE Glioblastoma is the most common primary central nervous system tumor in adults." | ( Kaye, AH; Luwor, RB; Mao, L; Morokoff, AP; Paradiso, L; Stylli, SS; Whitehead, CA, 2018) |
| "Glioblastoma is the most malignant and lethal subtype brain tumors with high risk of recurrence and therapeutic resistance." | ( Dong, Z; Du, S; Huang, J; Lei, T; Sun, M; Tong, R; Wang, H; Wang, Y; Yang, J; Yang, Y, 2018) |
| "Glioblastoma is a common primary brain tumor with aggressive malignancy, which results in poor outcomes, short survival time and high mortality." | ( Chen, H; Jin, X; Li, D; Zhang, G; Zhang, J, 2018) |
| "A glioblastoma is a common primary brain tumor that expresses microRNA-21 (miR-21), which inhibits the expression of pro-apoptotic genes such as phosphatase and tensin homologue (PTEN) and programmed cell death 4 (PDCD4)." | ( Jeong, JH; Kim, G; Kim, M; Lee, D; Lee, J; Lee, M; Lee, MS; Oh, J; Piao, C; Tan, X, 2018) |
| "Glioblastoma is the most aggressive primary brain tumor with a poor mean survival even with the current standard of care." | ( Johnson, H; White, FM, 2018) |
| "Glioblastoma is a devastating malignancy with a dismal survival rate." | ( Bourcier, AJ; Langan, ST; Liao, J; Mrowczynski, OD; Rizk, EB; Specht, CS, 2018) |
| "Glioblastoma is a highly malignant disease in critical need of expanded treatment options." | ( Bryant, WM; Dalton, HM; Farmer, G; King, PD; Lehman, NL; Li, X; McElroy, JP; Mifsud, CS; Sak, M; Urio, S; Usubalieva, A; Zumbar, CT, 2018) |
| "Glioblastoma is the most frequent and aggressive form of high-grade malignant glioma." | ( Frohnapfel, L; Kaina, B; Quiros, S; Ringel, F; Roos, WP, 2018) |
| "Glioblastoma is the most lethal type of primary tumours in the CNS." | ( Emanuelsson, I; Friman, T; Norlin, M; Wikvall, K, 2018) |
| "Glioblastoma is a malignant brain tumor that inevitably develops resistance to standard of care drug temozolomide (TMZ) due to a population of cells called cancer stem cells (CSCs)." | ( Chumakova, A; Lathia, JD, 2018) |
| "A glioblastoma is a primary CNS tumor that is more aggressive and lethal than other brain tumors." | ( Borges, HL; Clarêncio, J; Costa, SL; da Silva Velozo, E; de Faria Lopes, GP; de J Menezes-Filho, N; de Oliveira, DM; Dos Santos Costa, R; Freire, SM; Moura-Neto, V; Pereira, E; Pitanga, BPS; Rehen, SK; Silva, TCC, 2018) |
| "Glioblastoma is the most lethal primary brain tumor and poor survival of glioblastoma patients is attributed to the presence of glioma stem cells (GSCs)." | ( Aderetti, DA; Hira, VVV; Molenaar, RJ; van Noorden, CJF, 2018) |
| "Glioblastomas are the most frequently diagnosed and worst primary malignancy of the central nervous system, with very poor prognosis." | ( Fan, L; Gao, Y; He, Y; Meng, H; Sun, L; Xu, B; Xu, H; Zhou, Z, 2018) |
| "Glioblastoma is the most common and aggressive glioma, characterized by brain invasion capability." | ( Bonacorso, HG; Costa Nunes, F; Creczynski-Pasa, TB; de Melo, LJ; Feitosa, SC; Martins, MAP; Rode, M; Silva, AH; Silva, LB; Winter, E; Zanatta, N, 2018) |
| "Glioblastoma is the most aggressive type of brain cancer with the highest proliferation, invasion, and migration." | ( Chaithirayanon, K; Chongthammakun, S; Parakaw, T; Phuagkhaopong, S; Piromkraipak, P; Srihirun, S; Vivithanaporn, P, 2018) |
| "Glioblastoma is the most common and devastating type of malignant brain tumor." | ( Fujimori, H; Fujimoto, K; Ichimura, K; Imamichi, S; Ishikawa, E; Masutani, M; Masutomi, K; Matsumura, A; Matsushita, Y; Matsuzaki, S; Miki, S; Mukasa, A; Narita, Y; Nishikawa, R; Satomi, K; Takahashi, M; Tomiyama, A; Yamamoto, T, 2018) |
| "Glioblastoma is the most common malignant brain cancer in adults, with poor prognosis." | ( Azevedo, PO; Birbrair, A; Guerra, DAP; Mintz, A; Paiva, AE; Sena, IFG; Silva, WN, 2018) |
| "Glioblastoma is a primary malignant brain tumor with a poor prognosis." | ( Chen, Y; Cheng, YC; Chiu, CY; Kan, PC; Tsao, MJ, 2018) |
| "Glioblastoma is the most frequent and aggressive brain tumor due to its high capacity to migrate and invade normal brain tissue." | ( Bastida-Beristain, Y; Camacho-Arroyo, I; Fuente-Granada, M; González-Arenas, A; González-Orozco, JC; Hansberg-Pastor, V; Nicolas-Ortega, W; Valadez-Cosmes, P, 2018) |
| "Glioblastomas are a subtype of gliomas, which are the most aggressive and deadly form of brain tumours." | ( Adegoke, AO; Amos, S; Anson, DM; Darkwah, BO; Gryka, RJ; Huseman, ED; Jean-Louis, DS; Lin, S; Paris, RL; Stump, TA; Wilcox, RM, 2018) |
| "Glioblastoma is the most frequent and aggressive primary malignant tumor of the central nervous system with a gloomy prognosis." | ( Avril, S; Boury, F; Garcion, E; Hindré, F; Jérôme, C; Lajous, H; Lecomte, P; Lelièvre, B; Riva, R; Tétaud, C, 2018) |
| "Glioblastoma is one of the most malignant, angiogenic, and incurable tumors in humans." | ( Abdel Hadi, L; Anelli, V; Beretta, M; Campanella, R; Guarnaccia, L; Marfia, G; Moccia, F; Navone, S; Riboni, L; Tringali, C; Urechie, V, 2018) |
| "Glioblastoma is a highly aggressive brain tumor that is characterized by its unparalleled invasiveness." | ( Bernards, R; de Gooijer, MC; Guillén Navarro, M; van Tellingen, O; Wurdinger, T, 2018) |
| "Glioblastoma is the most common and aggressive primitive brain tumor in adults." | ( Bellu, L; Bergo, E; Berti, F; Caccese, M; Dal Pos, S; Della Puppa, A; Denaro, L; Gardiman, MP; Lombardi, G; Pambuku, A; Zagonel, V, 2018) |
| "Glioblastoma is the worst and most common primary brain tumor." | ( Azambuja, JH; Battastini, AMO; Beckenkamp, LR; Braganhol, E; de Oliveira, FH; Fernandes, MC; Figueiró, F; Gelsleichter, NE; Iser, IC; Scholl, JN; Sévigny, J; Spanevello, RM; Stefani, MA; Teixeira, HF; Wink, MR, 2019) |
| "Glioblastoma is the most common malignant brain tumor." | ( Chu, L; Liu, S; Mu, H; Ni, L; Song, Y; Sun, K; Wang, A; Wu, Z; Yan, X; Zhang, C; Zhao, M, 2018) |
| "Glioblastoma is the most common malignant brain cancer with a dismal prognosis." | ( Guo, S; Kelly, DF; Liang, Y; Murphy, S; Pham, L; Pridham, KJ; Sheng, Z; Varghese, RT; Young, S, 2018) |
| "Glioblastoma are among the most common forms of cancer affecting the central nervous system, and yet there is currently no effective means of treating them." | ( Lin, M; Yao, Z; Zhang, C; Zhao, N, 2019) |
| "Glioblastoma is the most common and lethal adult brain tumor." | ( Aldaz, P; Anastasov, N; Atkinson, MJ; Drakulic, D; Garcia, I; Garros-Regulez, L; Marjanovic Vicentic, J; Matheu, A; Nikolic, I; Puskas, N; Raicevic, S; Sampron, N; Stevanovic, M; Tasic, G; Vukovic, V, 2019) |
| "Glioblastoma is one of the most aggressive forms of cancers and has a poor prognosis." | ( Akiyama, T; Echizen, K; Funato, K; Hayashi, T; Ino, Y; Koyama-Nasu, R; Morishita, Y; Mukasa, A; Nasu-Nishimura, Y; Negishi, L; Saito, N; Shimizu, N; Tabar, V; Todo, T, 2018) |
| "Glioblastoma is the most common and lethal intracranial tumor type, characterized by high angiogenic and infiltrative capacities." | ( Bian, B; Han, L; Hayashi, H; Shimada, R; Si, N; Takagi, N; Yuan, B; Zhao, HY, 2018) |
| "Glioblastoma is the most common and aggressive primary brain tumor in adults." | ( Chen, X; Han, D; Hou, X; Liu, H; Liu, Z; Ma, J; Peng, F; Shen, C; Shu, M; Wang, K; Wang, L; Wang, X; Wu, J; Yang, G; Yin, Z; Zhang, D; Zhao, B; Zhao, S; Zhao, W; Zheng, Z; Zhong, C, 2018) |
| "Glioblastoma are highly immunosuppressive brain tumors that are known for their T cell paucity." | ( Bergers, G; Vella, G, 2018) |
| "Glioblastoma is a highly malignant tumor that easily acquires resistance to treatment." | ( Bae, SH; Gwak, H; Han, SS; Jang, H; Jeon, JH; Kang, SG; Kim, DK; Kim, HY; Kim, JK; Kim, SY; Kim, YH; Lee, BI; Lee, JH; Shim, JK; Shin, DH; You, HJ, 2018) |
| "Although glioblastomas are heterogeneous brain-infiltrating tumors, their treatment is mostly focused on the contrast-enhancing tumor mass." | ( Amit-Yousif, AJ; Barger, GR; Bosnyák, E; John, F; Juhász, C; Klinger, NV; Michelhaugh, SK; Mittal, S; Robinette, NL; Shah, KD, 2019) |
| "Glioblastoma is one of the most rapaciously growing cancer within the brain with an average lifespan of 12-15 months (5-year survival <3-4%)." | ( Gondaliya, P; Kalia, K; Muniswamy, VJ; Raval, N; Tambe, V; Tekade, RK, 2019) |
| "Glioblastomas are rich in blood vessels (i." | ( Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H, 2018) |
| "Glioblastoma is a highly vascularised tumour and there are few treatment options after disease recurrence." | ( Bellu, L; Brandes, AA; Daniele, B; De Salvo, GL; Eoli, M; Faedi, M; Farina, M; Gardiman, MP; Indraccolo, S; Lolli, I; Lombardi, G; Magni, G; Pace, A; Pambuku, A; Pasqualetti, F; Rizzato, S; Rudà, R; Soffietti, R; Zagonel, V, 2019) |
| "Glioblastoma is the most frequent primary malignant brain tumor." | ( Amelot, A; Bauchet, F; Bauchet, L; Bessaoud, F; Charissoux, M; Darlix, A; Duffau, H; Fabbro, M; Fabbro-Peray, P; Figarella-Branger, D; Mandonnet, E; Mathieu-Daude, H; Pallud, J; Rigau, V; Riondel, A; Sorbets, E; Taillandier, L; Tretarre, B; Zouaoui, S, 2019) |
| "Glioblastoma is the most common type of primary brain tumour in adults, and its pathogenesis is particularly complicated." | ( Chen, QX; Liao, JM; Liu, BH; Liu, JH; Xu, PF; Yang, JA; Yang, X; Yuan, FE, 2019) |
| "Human glioblastoma is a malignant and aggressive primary human brain solid tumor characterized by severe hypoxia." | ( He, X; Huang, S; Li, F; Qi, P; Zhang, T, 2019) |
| "Glioblastoma is the most malignant and widespread brain tumor in adults, with a rapid clinical course." | ( Aprile, C; Cavagnini, M; Ciocca, M; Facoetti, A; Lodola, L; Marenco, M; Nano, R; Orecchia, R; Pasi, F; Persico, MG; Valvo, F, 2019) |
| "Glioblastoma is the most common and most aggressive primary brain tumor, has high mortality, and affects both children and adults." | ( Krichevsky, AM; Uhlmann, EJ, 2019) |
| "Glioblastoma is the leading malignant glioma with a poor prognosis." | ( Matsuda, R; Morita, H; Motoyama, Y; Murakami, T; Nakagawa, I; Nakamura, M; Nakase, H; Nakazawa, T; Nishimura, F; Omoto, K; Shida, Y; Tanaka, Y; Tsujimura, T, 2019) |
| "Glioblastoma is the most fatal type of primary brain cancer, and current treatments for glioblastoma are insufficient." | ( Chern, JW; Hsin, LW; Hung, PY; Liu, JR; Yu, CW, 2019) |
| "Glioblastoma is the most common and malignant brain tumor, and current therapies confer only modest survival benefits." | ( Berg, HE; Hvinden, IC; Lundanes, E; Rise, F; Sachse, D; Sandberg, CJ; Skaga, E; Skottvoll, FS; Vik-Mo, EO; Wilson, SR, 2019) |
| "The treatment of glioblastoma is a critical health issue, owing to its resistance to chemotherapy." | ( Bureta, C; Komiya, S; Maeda, S; Nagano, S; Saitoh, Y; Sasaki, H; Setoguchi, T; Taniguchi, N; Tokumoto, H, 2019) |
| "The prognosis of glioblastoma is still dismal." | ( Panaro, MA; Porro, C; Prifti, E; Trotta, T, 2019) |
| "Glioblastoma is the most invasive form of brain tumor." | ( Arora, A; Somasundaram, K, 2019) |
| "Glioblastoma is a disease with high heterogeneity that has long been difficult for doctors to identify and treat." | ( Chen, X; Gao, M; Liu, Z; Shu, M; Wang, K; Wang, X; Ye, J; Yin, Z; Zhao, B; Zhao, H; Zhao, S; Zhao, W; Zheng, Z; Zhong, C, 2019) |
| "Glioblastoma is one of the most devastating human malignancies for which a novel efficient treatment is urgently required." | ( Fujimoto, K; Fukuoka, K; Hamada, A; Hayashi, M; Ichimura, K; Kikuchi, K; Maida, Y; Masutomi, K; Matsushita, Y; Miki, S; Mukasa, A; Narita, Y; Nishikawa, R; Shinkyo, R; Takahashi, M; Tamura, K; Yasukawa, M, 2019) |
| "Glioblastoma is a highly aggressive and treatment resistant primary brain tumor." | ( Devraj, K; Dubinski, D; Hattingen, E; Peters, KG; Plate, KH; Reiss, Y; Seifert, V; Senft, C, 2019) |
| "Glioblastoma is a high-grade glioma with poor prognosis even after surgery and standard therapy." | ( Faust, H; Gaunitz, F; Meixensberger, J; Oppermann, H; Yamanishi, U, 2019) |
| "Glioblastoma is a hostile brain tumor associated with high infiltration leading to poor prognosis." | ( Dos Santos Rodrigues, B; Lakkadwala, S; Singh, J; Sun, C, 2019) |
| "Glioblastoma is a grade IV malignant glioma with high recurrence and metastasis and faces a therapeutic obstacle that the blood-brain barrier (BBB) severely hinders the brain entry and efficacy of therapeutic drugs." | ( Chen, L; Chu, X; Gao, Z; Guan, Y; Huang, W; Jin, M; Liu, X; Meng, L; Xin, X; Xing, H, 2019) |
| "Glioblastoma is the most common, malignant and devastating type of primary brain tumor." | ( Cha, Z; Cheng, J; He, Y; Jia, J; Peng, Z; Qin, J; Xiang, H; Yu, H, 2019) |
| "Glioblastoma is the most common primary brain tumor in adults." | ( Al-Omaishi, S; Celebre, A; Chan, J; Das, S; Dirks, PB; Ghannad-Zadeh, K; Guan, J; Isaev, K; Kaskun, O; Moran, MF; Morrissy, AS; Munoz, DG; Reimand, J; Sachdeva, R; Smiljanic, S; Taylor, MD; Tong, J; Wilson, TM; Wu, M, 2019) |
| "Glioblastoma is the most aggressive and most lethal primary brain tumor in the adulthood." | ( Antoccia, A; Berardinelli, F; Buccarelli, M; di Masi, A; Leone, S; Mancuso, M; Muoio, D; Pallini, R; Ricci-Vitiani, L; Tanori, M, 2019) |
| "Glioblastoma is the most common and malignant primary brain tumour in adults, with a dismal prognosis." | ( Ashkan, K; Briscoe, AG; Burton, G; Hargreaves, IP; Heales, SJ; Holt, WV; Jung, J; Keatley, K; Littlewood, DTJ; McGeehan, JE; McGeehan, RE; Meunier, B; Pilkington, GJ; Rajala, N; Stromei-Cleroux, S; Wiltshire, T, 2019) |
| "Chemoresistance in glioblastoma is largely attributed to repair of temozolomide-induced DNA lesions by O6-methylguanine-DNA methyltransferase (MGMT)." | ( Chen, Z; Deng, S; Guo, M; Huang, G; Lei, B; Li, Y; Li, Z; Liu, Y; Pan, J; Qi, S; Wang, H; Xiang, W; Yi, GZ; Yu, L; Zhang, X, 2019) |
| "Glioblastoma is a highly malignant brain tumor with poor prognosis and survival rate because of a lack of effective diagnostic methods." | ( An, X; Chen, J; Feng, S; Gu, T; Jiang, Q; Meng, X; Ning, X; Shan, X; Zhang, J; Zhang, L, 2019) |
| "Glioblastoma is a lethal brain tumor, heavily infiltrated by tumor-associated myeloid cells (TAMCs)." | ( Anderson, CJ; Edinger, RS; Edwards, WB; Kohanbash, G; Kumar, R; Kurland, BF; McCarl, L; Nigam, S; Panigrahy, A, 2020) |
| "Glioblastoma is the most common and uncompromising primary brain tumour and is characterized by a dismal prognosis despite aggressive treatment regimens." | ( Chen, Z; Duffy, A; Hambardzumyan, D; Herting, CJ; Maximov, V; Shayakhmetov, DM; Szulzewsky, F, 2019) |
| "Glioblastoma is the brain tumor with the worst prognosis." | ( Erices, JI; Niechi, I; Quezada, C; Richter, HG; Rocha, JD; San Martín, R; Silva, P; Torres, Á; Uribe, D; Uribe-Ojeda, A, 2019) |
| "Glioblastoma is the most common and deadly type of brain cancer." | ( Chen, JY; Su, BC, 2020) |
| "Glioblastoma is the most common primary malignant tumor of the central nervous system, most of which occur in the brain." | ( Kuang, A; Ma, H; Pan, L; Shen, G; Su, M, 2020) |
| "Glioblastoma is the most common type of malignant brain tumor." | ( Bai, Y; Chen, Y; Ge, J; Jiang, S; Li, W; Ren, J; Wang, X; Wu, B; Xu, H; Zhao, G; Zhong, S, 2019) |
| "Glioblastoma is a devastating tumor affecting the central nervous system with infiltrative capacity, high proliferation rate and chemoresistance." | ( Azambuja, JH; Bona, NP; Braganhol, E; da Silveira, EF; de M Meine, B; de Oliveira, FH; Gelsleichter, NE; Mendonça, LT; Pedra, NS; Sekine, FG; Soares, MSP; Spanevello, RM; Spohr, L; Stefanello, FM, 2020) |
| "Since glioblastoma is a highly lethal and fast-growing brain tumor, new therapeutic strategies are urgently needed." | ( Ascari, LM; Cordeiro, Y; Faria, BM; Romão, LF; Soares, AG; Soares, JM; Souza, JM, 2019) |
| "Glioblastoma is one of the most common brain tumors with high invasion and malignancy." | ( Asemi, Z; Neamati, F, 2020) |
| "The treatment of glioblastoma is challenging for the clinician, due to its chemotherapeutic resistance." | ( Dunbar, GL; Maiti, P; Plemmons, A, 2019) |
| "Glioblastoma is the most frequent and lethal primary brain tumor." | ( Berens, ME; Burns, TC; Califano, A; Carlson, BL; Caron, A; Decker, PA; Dhruv, HD; Eckel-Passow, JE; Evers, L; Giannini, C; Grove, R; Jenkins, RB; Kitange, GJ; Klee, EW; Kollmeyer, TM; LaChance, DH; Ma, DJ; Marin, BM; Meyer, FB; Mladek, AC; O'Neill, BP; Parney, IF; Peng, S; Remonde, D; Sarkar, G; Sarkaria, JN; Schroeder, MA; Sulman, EP; Tian, S; Tran, NL; Vaubel, RA; Verhaak, RG; Wang, Q; Yan, H, 2020) |
| "Glioblastoma is uncommon in pediatric patients and particularly those with primitive neuronal components." | ( Kay, MD; Kuo, PH; Pariury, HE; Perry, A; Winegar, BA, 2020) |
| "Glioblastoma is the most malignant and prevalent brain tumor in adults." | ( Khathayer, F; Ray, SK; Taylor, MA, 2020) |
| "Glioblastoma is an aggressive central nervous system tumor with a 5-year survival rate of < 10%." | ( Hirose, Y; Ohba, S, 2020) |
| "Glioblastoma is the most aggressive brain tumor characterized by diffuse infiltration into the normal brain parenchyma." | ( Iwasawa, C; Mine, Y; Miyoshi, H; Morimoto, Y; Oishi, Y; Okano, H; Sampetrean, O; Saya, H; Tamura, R; Toda, M; Yoshida, K, 2020) |
| "Glioblastoma is the most common primary tumor of the central nervous system that develops chemotherapy resistance." | ( Chen, J; Chen, L; Hao, B; He, M; Li, X; Wang, C; Wu, H; Zhang, G; Zhang, T, 2020) |
| "Glioblastomas are the most aggressive type of brain tumour, with poor prognosis even after standard treatment such as surgical resection, temozolomide and radiation therapy." | ( Chiang, IT; Hsu, FT; Wang, WS, 2020) |
| "Glioblastoma is the deadliest neoplasm with the worst 5-year survival rate among all human cancers." | ( Lee, JE; Lee, JW; Moon, EY; Yoon, SS, 2020) |
| "Glioblastoma is one of the most difficult cancers to treat with a 5-year overall survival rate less than 5%." | ( Fang, F; Ji, Y; Li, H; Lu, Y; Qiu, P; Tang, H; Zhang, S, 2020) |
| "Pediatric glioblastomas are known to be one of the most dangerous and life-threatening cancers among many others regardless of the low number of cases reported." | ( Al-Youbi, AO; Bashammakh, AS; El-Shahawi, MS; Graham, RM; Leblanc, RM; Liyanage, PY; Vanni, S; Zhou, Y, 2020) |
| "Glioblastoma is the most aggressive central nervous system (CNS) neoplasm with high proliferation and tissue invasion capacity and is resistant to radio and chemotherapy." | ( da Silva Marques, M; de Moraes Vaz Batista Filgueira, D; de Souza Votto, AP; Horn, AP; Lettnin, AP; Marinho, MAG, 2021) |
| "Glioblastomas are generally incurable partly because monocytes, macrophages, and microglia in afflicted patients do not function in an antitumor capacity." | ( Bose, P; Dunn, JF; Kelly, J; Mirzaei, R; Mishra, MK; Poon, C; Rawji, K; Sarkar, S; Yang, R; Yong, VW; Zemp, FJ, 2020) |
| "Glioblastoma is a rapidly proliferating tumor." | ( Glas, M; Grosu, AL; Guberina, M; Guberina, N; Hau, P; Jabbarli, R; Jendrossek, V; Kebir, S; Lazaridis, L; Lübcke, W; Lüdemann, L; Niessen, M; Nour, Y; Oster, C; Pierscianek, D; Pöttgen, C; Scharmberg, C; Scheffler, B; Schmidt, T; Stuschke, M; Sure, U, 2020) |
| "Glioblastoma is a malignant brain tumor exhibiting highly aggressive proliferation and invasion capacities." | ( Hanashima, Y; Hara, H; Nakayama, T; Ozawa, Y; Sano, E; Sumi, K; Tatsuoka, J; Ueda, T; Yagi, C; Yamamuro, S; Yoshimura, S; Yoshino, A, 2020) |
| "Glioblastoma is the most common primary malignant brain tumor." | ( Aldape, K; Butler, M; Pommier, Y; Pongor, L; Quezado, M; Raffeld, M; Su, YT; Trepel, J; Wu, J; Xi, L, 2020) |
| "Glioblastoma is the most common primary brain tumor; survival is typically 12-18 months after diagnosis." | ( Moore, D; Padilla, F; Sheehan, D; Sheehan, J; Sheehan, K; Sulaiman, M; Xu, Z, 2020) |
| "Glioblastoma is one of the most aggressive tumors of the central nervous system." | ( Ghayour Mobarhan, M; Ghorbani, A; Jaliani, HZ; Lotfi, M; Sadeghnia, HR; Shahcheraghi, SH; Soukhtanloo, M, 2021) |
| "Glioblastomas are the most common malignant primary intrinsic brain tumors." | ( Le Rhun, E; Weller, M, 2020) |
| "Glioblastoma is the most devastating primary brain tumor and effective therapies are not available." | ( Azambuja, JH; Battastini, AMO; Beckenkamp, LR; Braganhol, E; de Oliveira, FH; Gelsleichter, NE; Lenz, GS; Michels, LR; Schuh, RS; Stefani, MA; Teixeira, HF; Wink, MR, 2020) |
| "Glioblastoma is the most common primary malignant brain tumor in adults." | ( Buelow, KL; Chinnaiyan, P; Graham, SF; Guastella, AR; Kant, S; Kesarwani, P; Kumar, P; Nakano, I, 2020) |
| "Glioblastoma is the most common malignant tumor of the brain, but its treatment outcomes can be improved by new therapeutic techniques using biocompatible materials." | ( Belousov, A; Khotimchenko, Y; Kovalev, V; Kumeiko, V; Malykin, G; Shved, N; Suprunova, I; Titov, S, 2020) |
| "Glioblastoma is one of the most aggressive human brain tumors." | ( Bryukhovetskiy, A; Bryukhovetskiy, I; Gulaia, V; Khotimchenko, R; Lyakhova, I; Piatkova, M; Romanishin, A; Sharma, A; Sharma, HS; Shmelev, M, 2020) |
| "Glioblastoma is the most common malignant primary brain tumor." | ( Ashley, DM; Friedman, HS; Khasraw, M; López, GY; Malinzak, M; Tan, AC, 2020) |
| "Glioblastoma is the most common primary brain tumor with poor survival rate and without effective treatment strategy." | ( Chen, WT; Chung, JG; Hsu, FT; Wu, CT, 2020) |
| "Glioblastoma is a highly invasive tumor, in which CCL5 expression correlates with shorter patient survival." | ( Breznik, B; Hrastar, B; Koprivnikar Krajnc, M; Lah Turnšek, T; Majc, B; Mlakar, J; Mlinar, M; Novak, M; Pestell, RG; Porčnik, A; Rotter, A; Stare, K, 2020) |
| "Glioblastoma is the most aggressive primary brain tumor leading to death in most of patients." | ( Bardiès, M; Belluco, S; Bonnefont-Rebeix, C; Brown, R; Buronfosse, T; Carozzo, C; Gehan, H; Khoshnevis, M; Louis, C; Marcon, L; Nennig, C; Ponce, F; Roger, T; Tillement, O; Zahi, I, 2020) |
| "Glioblastoma is characterized by the extensive vascularization with poor prognosis." | ( Bao, K; Chen, L; Huang, C; Peng, T; Wan, W; Yang, X; Zhang, X, 2020) |
| "Glioblastoma is an extremely aggressive glioma, resistant to radio and chemotherapy usually performed with temozolomide." | ( Arrais-Neto, AM; Carballo, GB; Matias, D; Pessoa, LS; Ribeiro, JH; Spohr, TCLSE, 2020) |
| "Glioblastoma is a common, malignant brain tumor whose disease incidence increases with age." | ( Ahnert, P; Holland, H; Johnson, AA; Kirsten, H; Krupp, W; Meixensberger, J; Mueller, W; Richter, M; Rohani, L; Rudolf, D; Schmidt, C; Schulz, RM; Wallenborn, M; Xu, LX, 2020) |
| "Glioblastoma is the most common primary malignant tumor of the central nervous system which is the most lethal type of primary brain tumor in adults with the survival time of 12-15 months after the initial diagnosis." | ( Ahmadi-Zeidabadi, M; Ashta, A; Motalleb, G, 2020) |
| "Glioblastoma is devastating cancer with a high frequency of occurrence and poor survival rate and it is urgent to discover novel glioblastoma-specific antigens for the therapy." | ( Liu, C; Liu, R; Lu, Y; Zhang, F; Zhang, H, 2020) |
| "Glioblastoma is the most aggressive central nervous system tumour." | ( Alamón, C; Cabral, P; Cerecetto, H; Couto, M; Dagrosa, MA; Nievas, S; Perona, M; Teixidor, F; Viñas, C, 2020) |
| "Glioblastoma is a primary brain tumor with a poor prognosis despite multimodal therapy including surgery, radiotherapy and alkylating chemotherapy." | ( Mason, WP; Richardson, PG; Roth, P; Weller, M, 2020) |
| "Glioblastoma is one of the most common and most aggressive brain cancers." | ( Cheng, AY; Chien, YC; Hsieh, YH; Lee, HC; Yu, YL, 2020) |
| "Glioblastoma is a fast-growing primary brain tumor observed in adults with the worst prognosis." | ( Aldanan, S; Alghareeb, WA; Alhussain, H; AlNajjar, FH; Alsaeed, E; Alsharm, AA; Altwairgi, AK; Balbaid, AAO; Orz, Y, 2021) |
| "Glioblastoma is the most aggressive form of primary brain cancer, with a median survival of 12-15 months." | ( Drill, M; Hamilton, JA; Jones, NC; Kan, LK; Monif, M; O'Brien, TJ; Powell, KL, 2020) |
| "Glioblastomas are the most frequent and aggressive form of primary brain tumors with no efficient cure." | ( Jensen, ON; Karatsai, O; Rędowicz, MJ; Shliaha, P; Stasyk, O, 2020) |
| "Glioblastoma is a malignant brain tumour with a median survival of 14." | ( Clarke, PA; Fay, M; Lovato, T; Marlow, M; McCrorie, P; Mistry, J; Rahman, R; Ritchie, AA; Smith, SJ; Taresco, V; Ward, I, 2020) |
| "Glioblastoma is an aggressive, fast-growing brain tumor influenced by the composition of the tumor microenvironment (TME) in which mesenchymal stromal cell (MSCs) play a pivotal role." | ( Giacomelli, C; Marchetti, L; Martini, C; Pietrobono, D; Trincavelli, ML, 2020) |
| "In particular, glioblastoma is one of the most lethal brain tumors." | ( Fermi, V; Herold-Mende, C; Roesch, S; Romero-Nieto, C; Rominger, F, 2020) |
| "Glioblastoma is the most common and aggressive type of brain tumor with high recurrence and fatality rates." | ( Aoki, T; Hara, A; Hirono, S; Ihara, F; Iwadate, Y; Kobayashi, M; Koyama-Nasu, R; Matsutani, T; Motohashi, S; Nakayama, T; Takami, M; Toyoda, T, 2021) |
| "Glioblastoma is the most frequent aggressive primary brain tumor amongst human adults." | ( Arús, C; Candiota, AP; Julià-Sapé, M; Ledesma-Carbayo, MJ; Núñez, LM; Romero, E; Santos, A; Vellido, A, 2020) |
| "Glioblastoma is the most common and aggressive type of cancer in the brain; its poor prognosis is often marked by reoccurrence due to resistance to the chemotherapeutic agent temozolomide, which is triggered by an increase in the expression of DNA repair enzymes such as MGMT." | ( Barnes, S; Burma, S; Buszczak, M; Conacci-Sorrell, M; Han, J; Kanji, S; Kilgore, JA; Lafita-Navarro, MC; Venkateswaran, N; Williams, NS, 2020) |
| "Glioblastoma is the most severe form of brain cancer." | ( Caputto, BL; Caverzán, MD; Milla Sanabria, LN; Palacios, RE; Prucca, CG; Rivarola, VA; Rodríguez, LB; Vilchez, ML, 2021) |
| "Glioblastoma is the most common and the deadliest brain cancer." | ( Cielecka-Piontek, J; Kaczmarek, M; Kleszcz, R; Krajka-Kuźniak, V; Majchrzak-Celińska, A; Paluszczak, J; Studzińska-Sroka, E; Wierzchowski, M; Zielińska-Przyjemska, M, 2021) |
| "Glioblastoma is a type of aggressive brain tumor that grows very fast and evades surrounding normal brain, lead to treatment failure." | ( Kim, DH; Kim, YN; Koo, KH; Lee, CH; Lee, EJ; Park, J; Park, JB; Shim, J; Sung, JY, 2020) |
| "Glioblastoma is the most common malignant tumor of the central nervous system and is treated with a combination of surgery, radiation and chemotherapy." | ( Kaji, T; Kitabatake, K; Tsukimoto, M, 2021) |
| "Glioblastoma is a severe type of brain tumor with a poor prognosis and few therapy options." | ( Andrade Tomaz, M; de Souza, I; Karolynne Seregni Monteiro, L; Menck, CFM; Molina Silva, M; Reily Rocha, A; Rocha, CRR; Rodrigues Gomes, L; Teatin Latancia, M, 2020) |
| "Glioblastoma is a highly malignant brain tumor with limited treatment options and short survival times." | ( Efferth, T; Giordano, FA; Greten, HJ; Kadioglu, O; Mayr, K; Saeed, MEM; Wenz, F; Yildirim, A, 2021) |
| "Glioblastoma is one of the leading cancer-related causes of death of the brain region and has an average 5-year survival rate of less than 5%." | ( Chen, CJ; Chung, YH; Hsu, LS; Yeh, LT, 2020) |
| "Glioblastoma is the most lethal tumor of the central nervous system, presenting a very poor prognostic, with a survival around 16 months." | ( Amaral da Silva, VD; Costa, SL; da Silva, KC; David, JM; David, JP; de Faria Lopes, GP; de Fátima Costa, M; Dos Santos, BL; Moura-Neto, V; Nascimento, RP; Oliveira, MDN; Ulrich, H, 2021) |
| "Glioblastoma is the most common lethal malignant intracranial tumor with a low 5-year survival rate." | ( Dong, CY; Hong, S; Huang, QX; Liu, FS; Zhang, XZ; Zheng, DW; Zhong, ZL, 2021) |
| "Glioblastoma is one of the most invasive tumors of the central nervous system, and has a high degree of malignancy and poor prognosis." | ( Guo, CY; Hu, P; Jiang, QG; Kuang, H; Lv, YX; Xiao, ZM; Zhang, WH; Zhu, YG, 2021) |
| "Glioblastoma is the deadliest brain tumor in adults, and the standard of care consists of surgery followed by radiation and treatment with temozolomide." | ( Bensinger, SJ; Bhat, K; Cheng, F; Cloughesy, TF; He, L; Ioannidis, A; Kornblum, HI; Liau, LM; Nathanson, D; Nghiemphu, PL; Pajonk, F; Saki, M; Tsang, J; Zhang, L, 2021) |
| "Glioblastoma is the most aggressive cancer among primary brain tumours." | ( Bošnjak, R; Breznik, B; Lah, TT; Majc, B; Marinelli, O; Mlinar, M; Nabissi, M; Novak, M; Pena Almidon, MA; Zomer, R; Žvar Baškovič, B, 2021) |
| "Glioblastoma is characterized by the robust infiltration of immunosuppressive tumor-associated myeloid cells (TAMCs)." | ( Burga, R; Burns, M; Castro, B; Chandel, NS; Cordero, A; Gao, P; Han, Y; Horbinski, CM; Hou, D; Lee-Chang, C; Lesniak, MS; Lopez-Rosas, A; Miska, J; Rashidi, A; Reshetnyak, YK; Sampat, S; Stoolman, JS; Xiao, T; Zhang, P, 2021) |
| "Glioblastoma is the most malignant brain tumor and presents high resistance to chemotherapy and radiotherapy." | ( Castresana, JS; De La Rosa, J; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A; Zazpe, I; Zelaya, MV, 2021) |
| "Glioblastoma is the most common primary malignant brain tumor that is usually considered fatal even with treatment." | ( Chang, KY; Chien, CH; Chuang, JY; Hsueh, WT, 2021) |
| "Glioblastoma is an aggressive form of brain cancer." | ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Howell, A; Jefferies, S; Kelly, C; Kernohan, A; Kurian, KM; McAleenan, A; Robinson, T; Schmidt, L; Spiga, F; Vale, L; Wragg, C, 2021) |
| "Glioblastoma is the most common malignant brain tumor, currently treated by surgery followed by concomitant radiotherapy and temozolomide-based chemotherapy." | ( Chabardès, S; Fulbert, C; Ratel, D, 2021) |
| "Glioblastoma is the most common malignant primary brain tumor." | ( Bello-Alvarez, C; Camacho-Arroyo, I, 2021) |
| "Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics." | ( Boockvar, J; Brahmbhatt, H; Gao, S; Gonzalez, C; Jamil, E; Khan, MB; MacDiarmid, J; Mugridge, N; Ruggieri, R; Sarkaria, JN; Symons, M; Tran, NL, 2021) |
| "Glioblastoma is the most aggressive and common intracranial malignant tumor, and the prognosis is still poor after various treatments." | ( Guo, Y; Jia, M; Song, Y; Sun, Y; Wang, Y; Yu, P; Zhao, L, 2021) |
| "Glioblastomas are the most common and aggressive primary brain tumors in adults, and patients with glioblastoma have a median survival of 15 months." | ( Bello-Alvarez, C; Camacho-Arroyo, I; González-Arenas, A; Moral-Morales, AD, 2021) |
| "Glioblastoma is a primary brain cancer with a near 100% recurrence rate." | ( Ahmed, AU; Ali, ES; Atashi, F; Baisiwala, S; Ben-Sahra, I; Horbinski, CM; James, CD; Kumthekar, P; Lee, G; Lesniak, MS; Miska, J; Park, CH; Saathoff, MR; Savchuk, S; Shireman, JM; Stupp, R, 2021) |
| "Glioblastoma is the most malignant tumor of the brain associated with poor prognosis and outcome, and hence there is an urgent need to develop novel treatments for glioblastoma." | ( de Vega, S; Hara, H; Inoue, S; Nakamura, S; Okada, Y; Shimazawa, M; Tsuji, S; Yamada, T, 2021) |
| "Glioblastoma is the most common and aggressive type of malignant brain tumor with poor survival and limited therapeutic options." | ( Ge, C; Li, J; Liu, HK; Liu, L; Qian, Y, 2021) |
| "Glioblastoma is the most frequently diagnosed type of primary brain tumour in adults." | ( Collis, SJ; Rominiyi, O, 2022) |
| "The progression of glioblastomas is associated with a variety of neurological impairments, such as tumor-related epileptic seizures." | ( Hörnschemeyer, J; Kirschstein, T; Lange, F, 2021) |
| "Glioblastoma is a high-grade glial neoplasm with a patient survival of 12-18 months." | ( Bates, SJ; Bianchetti, E; Nguyen, TTT; Roth, KA; Siegelin, MD, 2021) |
| "Glioblastoma is the most common primary malignancy of the central nervous system with a dismal prognosis." | ( Alhalabi, OT; Baumgartner, U; Day, BW; Fletcher, MNC; Goidts, V; Göttmann, M; Hai, L; Hansen-Palmus, L; Herold-Mende, C; Hielscher, T; Kessler, T; Lokumcu, T; Nakano, I; Phillips, E; Puccio, L; Rahman, S; Sahm, F; Schlue, S; Wick, W; Wittmann, E, 2022) |
| "Most recurrent glioblastomas are temozolomide resistant." | ( Chang, YW; Chen, CY; Chen, YC; Hsu, JB; Huang, SW; Kuo, DP; Lee, GA; Li, YT; Lin, WL, 2021) |
| "Glioblastoma is a malignant brain tumor with poor prognosis that rapidly acquires resistance to available clinical treatments." | ( Chien, CL; Liao, ML; Luo, EW, 2021) |
| "Glioblastoma is a highly malignant brain tumor with no curative treatment options, and immune checkpoint blockade has not yet shown major impact." | ( Bachmann, F; Dietrich, PY; Espinoza, FI; Genoud, V; Lane, HA; Marinari, E; McSheehy, P; Rochemont, V; Walker, PR, 2021) |
| "Glioblastoma is a lethal neoplasm with few effective therapy options." | ( Gao, Y; Ji, J; Liu, A; Qiu, N; Xi, Y; Xu, J; Yang, X; Zhai, G, 2021) |
| "Glioblastoma is the most common primary brain malignancy and carries with it a poor prognosis." | ( Camphausen, K; Degorre, C; Mathen, P; Tofilon, P, 2021) |
| "Glioblastoma is the most common primary malignant brain tumor with an incidence of 5/100,000 inhabitants/year and a 5-year survival rate of 6." | ( Baloglu, S; Cebula, H; Chibbaro, S; De Mathelin, M; Gangi, A; Mallereau, CH; Noblet, V; Noel, G; Proust, F; Todeschi, J, 2022) |
| "Glioblastoma is the most serious type of brain cancer with poor prognosis." | ( Li, J; Wang, N; Xin, Q; Xu, N, 2021) |
| "Glioblastoma is the most life-threatening tumour of the central nervous system." | ( Alves-Leon, SV; Campanati, L; Eugenio, M; Marcondes de Souza, J; Müller, N; Romão, LF; Sant'Anna, C, 2021) |
| "Glioblastoma is the most common and most aggressive primary brain cancer in adults." | ( Burgess, C; FitzJohn, T; Kaye, AH; O'Rawe, M; Pandey, R; Sim, D; Tan, ST; Wickremesekera, AC; Young, D, 2022) |
| "Glioblastoma is the most common intracranial primary malignant tumor, which leads to the poor quality of life of patients and has a high recurrence rate." | ( Cui, HJ; Lu, XY; Wan, SC; Wang, ZZ; Zhao, EH, 2021) |
| "Glioblastoma is the most frequent and malignant primary brain tumor." | ( Becker, A; Burger, MC; Clusmann, H; Delev, D; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Güresir, E; Hau, P; Heiland, DH; Herrlinger, U; Krex, D; Nemeth, R; Potthoff, AL; Radbruch, A; Sabel, M; Schaub, C; Schilling, J; Schlegel, U; Schmid, M; Schneider, M; Schnell, O; Schuss, P; Seidel, C; Steinbach, JP; Tabatabai, G; Thon, N; Vatter, H; Weller, J; Winkler, F; Zeyen, T, 2022) |
| "Glioblastoma is the central nervous system tumor with the highest mortality rate, and the clinical effectiveness of chemotherapy is low." | ( Cao, Y; Cheng, B; Gao, D; Hong, X; Qin, D; Wang, L; Zhou, H, 2022) |
| "Glioblastoma is the commonest primary brain cancer in adults whose outcomes are amongst the worst of any cancer." | ( Akkari, L; Borst, GR; Coope, DJ; McBain, C; O'Connor, J; Quinones-Hinojosa, A; Trifiletti, DM; Waqar, M, 2022) |
| "Glioblastoma is the most common and lethal malignant brain tumor." | ( Bruinsmann, FA; de Cristo Soares Alves, A; de Fraga Dias, A; Figueiró, F; Lopes Silva, LF; Raffin Pohlmann, A; Sonvico, F; Stanisçuaski Guterres, S; Visioli, F, 2022) |
| "Glioblastoma is the most common and fatal primary malignant tumor in the central nervous system, and the prognosis is poor." | ( Chen, J; Liang, RS; Liu, S; Wang, CH; Zhang, Q; Zhuang, BB; Zhuang, YD, 2022) |
| "Glioblastomas are the most aggressive brain tumors for which therapeutic options are limited." | ( Carson, SC; Colley, SB; Faia, C; Ingraham Iv, CH; Jursic, BS; Lassak, A; Peruzzi, F; Plaisance-Bonstaff, K; Reiss, K; Stalinska, J; Vittori, C, 2022) |
| "Glioblastoma is a highly aggressive brain tumor characterized by high recurrence and poor prognosis." | ( Huang, J; Su, F; Xu, L; Zhong, X; Zhou, Y, 2022) |
| "In humans, glioblastoma is the most prevalent primary malignant brain tumor." | ( Gigli, G; Leporatti, S; Persano, F, 2022) |
| "Glioblastoma is one of the deadliest malignant gliomas." | ( Hacioglu, C; Kar, F, 2023) |
| "Glioblastoma is a deadly cancer tumor in the brain and has a survival rate of about 15 months." | ( Jang, WI; Jeong, HJ; Jung, CW; Kim, EH; Kim, HJ; Kim, JY; Lee, WS; Park, MJ, 2022) |
| "Glioblastoma is the most prevalent and aggressive tumor subtype of glioma." | ( Alyautdin, R; Chubarev, V; Grigorevskikh, E; Ismail, N; Merkulov, V; Petrenko, D; Smolyarchuk, E; Sologova, S; Syzrantsev, N, 2022) |
| "Glioblastoma is the most aggressive form of brain cancer, characterised by high proliferation rates and cell invasiveness." | ( Astori, G; Belli, R; Bernardi, M; Bozza, A; Catanzaro, D; Celli, P; Chieregato, K; Menarin, M; Merlo, A; Milani, G; Peroni, D; Pozzato, A; Pozzato, G; Raneri, FA; Ruggeri, M; Volpin, L, 2022) |
| "Glioblastoma is the most aggressive form of brain tumor, accounting for the highest mortality and morbidity rates." | ( Baig, MH; Cho, JY; Dong, JJ; Hatiboglu, MA; Imran, MA; Khan, I; Khan, MI; Mahfooz, S, 2022) |
| " Glioblastoma is the most aggressive and diffusely infiltrative primary brain tumor." | ( Ansari, A; Prajapati, HP, 2023) |
| "Glioblastoma is the most common malignant brain cancer with dismal survival and prognosis." | ( Chen, CC; Chen, Y; Grigore, FN; Jin, J; Lan, Q; Li, M; Li, S; Ma, J; Wang, J; Wang, Q; Wu, G; Xu, H; Zhu, H, 2022) |
| "Glioblastoma is a fatal brain tumor with a bleak prognosis." | ( Sowers, LC; Sowers, ML, 2022) |
| "(1) Background: Glioblastoma is the most frequent and lethal primary tumor of the central nervous system." | ( Celis-López, MÁ; Cid-Sánchez, DR; Contreras-Palafox, GA; Flores-Vázquez, JG; Gutiérrez-Aceves, GA; Heredia-Gutiérrez, JC; Hernández-Sánchez, LC; Macías-González, MDS; Moreno-Jiménez, S; Moscardini-Martelli, J; Olmos-Guzmán, A; Ortiz-Arce, CS; Pérez, SR; Rodríguez-Camacho, A; Suárez-Campos, JJE; Torres-Ríos, JA, 2022) |
| "Glioblastoma is the most frequent and lethal primary central nervous system tumor in adults, accounting for around 15% of intracranial neoplasms and 40-50% of all primary malignant brain tumors, with an annual incidence of 3-6 cases per 100,000 population." | ( Chang, PC; Chen, HY; Feng, SW; Huang, SM; Hueng, DY; Li, YF, 2022) |
| "Glioblastoma is the most aggressive and lethal brain tumor in adults with highly invasive properties." | ( Chabang, N; Kwanthongdee, J; Munyoo, B; Saengsawang, W; Sunrat, C; Tuchinda, P; Uppakara, K, 2022) |
| "Glioblastoma is one of the most common malignant tumors in the brain, and these glioblastoma patients have very poor prognosis." | ( Ge, FH; Hao, RR; Li, WX; Shen, JL; Wang, XL; Xu, AB; Xu, P; Xu, Z, 2022) |
| "Glioblastoma is rather recalcitrant to existing therapies and effective interventions are needed." | ( Ding, B; Ding, X; Gao, S; He, M; Heger, M; Jiao, X; Xu, N; Yu, Y; Zhang, J; Zhang, M; Zhang, S, 2022) |
| "Glioblastoma is the most prevalent and malignant brain tumor identified in adults." | ( Chagas, RCR; Gonçalves, AS; Melo, ESA; Netto, JB; Oliveira, AGS; Reis, RM; Ribeiro, RIMA; Santiago, LR; Santos, DM; Santos, HB; Sousa, LR; Thomé, RG, 2022) |
| "Glioblastoma is the most common and aggressive primary brain tumor, characterized by its high chemoresistance and the presence of a cell subpopulation that persists under hypoxic niches, called glioblastoma stem-like cells (GSCs)." | ( Alarcón, S; Delgado, J; Erices, JI; Fernández-Gajardo, R; Melo, R; Niechi, I; Quezada Monrás, C; Rocha, JD; Salazar-Onfray, F; San Martín, R; Uribe, D, 2022) |
| "Glioblastoma is one of the most common intracranial malignant tumors with an unfavorable prognosis, and iron metabolism as well as ferroptosis are implicated in the pathogenesis of glioblastoma." | ( Chen, B; Ge, F; Hao, K; Hao, R; Jiang, W; Li, K; Shen, J; Wang, Z; Xu, A; Yang, W; Zheng, Y, 2022) |
| "Glioblastoma is a malignant primary brain tumor that affects approximately 250,000 new patients per year worldwide." | ( Aquilanti, E; Wen, PY, 2022) |
| "Glioblastomas are tumors that present a high mortality rate." | ( Andrade, CMB; Branco, CLB; Costa, SA; Cruz, L; da Conceição, AGB; da Silva, KP; Ferrarini, SR; Pires, J; Reis, ÉM; Sinhorin, AP, 2022) |
| "Glioblastoma is the most common brain tumor with dismal outcomes in adults." | ( Amano, T; Fujiwara, M; Hirose, H; Matsuo, S; Miyamatsu, Y; Nakamizo, A; Shimamura, T; Yoshimoto, K, 2022) |
| "Glioblastoma is a prevalent malignant brain tumor and despite clinical intervention, tumor recurrence is frequent and usually fatal." | ( Carter, CL; Harris, BT; Liapis, E; O'Neill, KC; Perlin, DS, 2022) |
| "Glioblastoma is the most common brain tumor." | ( Balkanov, AS; Belyaev, AY; Glazkov, AA; Kobyakov, GL; Rozanov, ID; Shmakov, PN; Strunina, YV; Telysheva, EN; Usachev, DY, 2022) |
| "Glioblastoma is the most common brain tumor." | ( Balkanov, AS; Belyaev, AY; Glazkov, AA; Kobyakov, GL; Rozanov, ID; Shmakov, PN; Strunina, YV; Telysheva, EN; Usachev, DY, 2022) |
| "Glioblastoma is the most common malignancy of central nervous system, and its prognosis remains very poor mainly due to chemotherapeutic resistance." | ( Chen, XZ; Xu, HB; Xue, F; Yu, ZL, 2023) |
| "Treating glioblastoma is difficult due to complicating factors, and novel therapeutic strategies are required to overcome resistance." | ( Cao, J; Fu, Z; Gu, Y; Li, Y; Lin, P; Yan, H, 2022) |
| "Glioblastoma is the most common and most aggressive type of primary brain tumor." | ( Bu, XY; Cheng, X; Kong, LF; Luo, JC; Qu, MQ; Wang, YW; Yan, ZY; Yang, DY; Zhao, YW, 2023) |
| "Glioblastoma is the most lethal primary brain cancer." | ( Abram, S; Aiken, RD; Ansstas, G; Ashkan, K; Avigan, DE; Baskin, DS; Battiste, JD; Bosch, ML; Bota, DA; Boynton, AL; Brem, S; Brenner, AJ; Campian, JL; Chaudhary, R; Cobbs, CS; D'Andre, S; Dunbar, EM; Elinzano, H; Etame, AB; Ewend, MG; Fink, KL; Geoffroy, FJ; Giglio, P; Gligich, O; Goldlust, SA; Grewal, J; Heth, JA; Iwamoto, FM; Kesari, S; Khagi, S; Kim, L; Krex, D; Lacroix, M; Lee, IY; Liau, LM; Lillehei, K; Lindhorst, SM; Loudon, WG; Lovick, DS; Lutzky, J; Martinez, NL; Mathieu, D; May, SA; Meisel, HJ; Mikkelsen, T; Moshel, YA; Mulholland, PJ; Nadji-Ohl, M; Nam, JY; New, PZ; Peak, S; Pearlman, ML; Petrecca, K; Piccioni, DE; Pillainayagam, CP; Pluard, TJ; Portnow, J; Prins, RM; Salacz, ME; Sanchin, L; Schulder, M; Sloan, A; Taylor, LP; Thompson, RC; Toms, SA; Tran, DD; Trusheim, JE; Tse, V; Villano, JL; Wagner, SA; Walbert, T; Walter, KA; Wu, JK, 2023) |
| "Glioblastoma is the most lethal primary brain cancer." | ( Abram, S; Aiken, RD; Ansstas, G; Ashkan, K; Avigan, DE; Baskin, DS; Battiste, JD; Bosch, ML; Bota, DA; Boynton, AL; Brem, S; Brenner, AJ; Campian, JL; Chaudhary, R; Cobbs, CS; D'Andre, S; Dunbar, EM; Elinzano, H; Etame, AB; Ewend, MG; Fink, KL; Geoffroy, FJ; Giglio, P; Gligich, O; Goldlust, SA; Grewal, J; Heth, JA; Iwamoto, FM; Kesari, S; Khagi, S; Kim, L; Krex, D; Lacroix, M; Lee, IY; Liau, LM; Lillehei, K; Lindhorst, SM; Loudon, WG; Lovick, DS; Lutzky, J; Martinez, NL; Mathieu, D; May, SA; Meisel, HJ; Mikkelsen, T; Moshel, YA; Mulholland, PJ; Nadji-Ohl, M; Nam, JY; New, PZ; Peak, S; Pearlman, ML; Petrecca, K; Piccioni, DE; Pillainayagam, CP; Pluard, TJ; Portnow, J; Prins, RM; Salacz, ME; Sanchin, L; Schulder, M; Sloan, A; Taylor, LP; Thompson, RC; Toms, SA; Tran, DD; Trusheim, JE; Tse, V; Villano, JL; Wagner, SA; Walbert, T; Walter, KA; Wu, JK, 2023) |
| "Glioblastoma is the most lethal primary brain cancer." | ( Abram, S; Aiken, RD; Ansstas, G; Ashkan, K; Avigan, DE; Baskin, DS; Battiste, JD; Bosch, ML; Bota, DA; Boynton, AL; Brem, S; Brenner, AJ; Campian, JL; Chaudhary, R; Cobbs, CS; D'Andre, S; Dunbar, EM; Elinzano, H; Etame, AB; Ewend, MG; Fink, KL; Geoffroy, FJ; Giglio, P; Gligich, O; Goldlust, SA; Grewal, J; Heth, JA; Iwamoto, FM; Kesari, S; Khagi, S; Kim, L; Krex, D; Lacroix, M; Lee, IY; Liau, LM; Lillehei, K; Lindhorst, SM; Loudon, WG; Lovick, DS; Lutzky, J; Martinez, NL; Mathieu, D; May, SA; Meisel, HJ; Mikkelsen, T; Moshel, YA; Mulholland, PJ; Nadji-Ohl, M; Nam, JY; New, PZ; Peak, S; Pearlman, ML; Petrecca, K; Piccioni, DE; Pillainayagam, CP; Pluard, TJ; Portnow, J; Prins, RM; Salacz, ME; Sanchin, L; Schulder, M; Sloan, A; Taylor, LP; Thompson, RC; Toms, SA; Tran, DD; Trusheim, JE; Tse, V; Villano, JL; Wagner, SA; Walbert, T; Walter, KA; Wu, JK, 2023) |
| "Glioblastoma is the most lethal intracranial malignant tumor, for which the five-year overall survival rate is approximately 5%." | ( Ahmad, N; Chen, G; Fu, P; Jiang, X; Li, J; Liu, G; Liu, J; Shi, G; Song, X; Sun, M; Wang, J; Yang, F; Yu, H; Zhang, R; Zhang, Y; Zhou, Y; Zhuang, J, 2023) |
| "Glioblastoma is the most lethal intracranial malignant tumor, for which the five-year overall survival rate is approximately 5%." | ( Ahmad, N; Chen, G; Fu, P; Jiang, X; Li, J; Liu, G; Liu, J; Shi, G; Song, X; Sun, M; Wang, J; Yang, F; Yu, H; Zhang, R; Zhang, Y; Zhou, Y; Zhuang, J, 2023) |
| "Glioblastoma is the most lethal intracranial malignant tumor, for which the five-year overall survival rate is approximately 5%." | ( Ahmad, N; Chen, G; Fu, P; Jiang, X; Li, J; Liu, G; Liu, J; Shi, G; Song, X; Sun, M; Wang, J; Yang, F; Yu, H; Zhang, R; Zhang, Y; Zhou, Y; Zhuang, J, 2023) |
| "Glioblastoma is the most common primary malignant tumor of the central nervous system." | ( Ahmadi-Zeidabadi, M; Amirinejad, M; Jomehzadeh, A; Khoei, S; Kordestani, Z; Larizadeh, MH; Yahyapour, R, 2023) |
| "Glioblastoma is the most common primary malignant tumor of the central nervous system." | ( Ahmadi-Zeidabadi, M; Amirinejad, M; Jomehzadeh, A; Khoei, S; Kordestani, Z; Larizadeh, MH; Yahyapour, R, 2023) |
| "Glioblastoma is the most common and fatal primary glioma and has a severe prognosis." | ( Cheon, GJ; Jang, HJ; Kang, KW; Lee, YS; Park, CR; Song, MG; Youn, H, 2023) |
| "Glioblastoma is the most common malignant tumor of the central nervous system, which originates from glial cells and corresponding precursors." | ( Cheng, P; Han, Q; Ma, H; Yang, H; Zhao, M; Zhao, Y, 2022) |
| "Glioblastoma is among the most lethal cancers, with no known cure." | ( Bhatt, H; Brown, JMC; Gray, WP; Ormonde, C; Sharouf, F; Siebzehnrubl, FA; Spencer, R; Zaben, M, 2023) |
| "Brain tumor glioblastoma is one of the worst types of cancer." | ( Amerhanova, SK; Antipin, IS; Bakhtiozina, LR; Kadirov, MK; Lyubina, AP; Mansurova, EE; Nizameev, IR; Semenov, VE; Shulaeva, MM; Voloshina, AD; Ziganshina, AY, 2023) |
| "Glioblastoma is characterized by extensive vascularization and is highly resistant to current therapy." | ( Xu, T; Zhang, Q; Zhao, J, 2023) |
| "Glioblastoma is the most common primary cranial malignancy, and chemotherapy remains an important tool for its treatment." | ( Cai, HR; Cui, HJ; Sun, W; Tang, WH; Yang, H; Zhang, ZN; Zhao, EH, 2023) |
| "Glioblastoma is a heterogeneous tumor for which effective treatment options are limited and often insufficient." | ( Beechem, JM; Cimino, PJ; Danaher, P; Glod, J; Hurth, K; Kim, Y; McEachron, TA; Warren, S; Zada, G, 2023) |
| "Glioblastomas are highly malignant brain tumors that derive from brain-tumor-initiating cells (BTICs) and can be subdivided into several molecular subtypes." | ( Ammer, LM; Dettmer, K; Hau, P; Heckscher, S; Jachnik, B; Leidgens, V; Moeckel, S; Oefner, PJ; Proescholdt, M; Rauer, L; Riemenschneider, MJ; Seliger, C; Vollmann-Zwerenz, A; Wüster, AL, 2023) |
| "Glioblastoma is one of the most malignant and lethal forms of primary brain tumors in adults." | ( Alexiou, GA; Galani, V; Giannakopoulou, M; Kyritsis, AP; Lazari, D; Papagrigoriou, T; Tsekeris, P; Tsiftsoglou, OS; Tzima, E; Zikou, A; Zoi, V, 2023) |
| "Glioblastoma is one of the most devastating and incurable cancers due to its aggressive behaviour and lack of available therapies, being its overall-survival from diagnosis ∼14-months." | ( Blanco-Acevedo, C; Castaño, JP; Doval-Rosa, C; Fuentes-Fayos, AC; G-García, ME; Gahete, MD; Jiménez-Vacas, JM; López, M; Luque, RM; Martín-Colom, J; Montero-Hidalgo, AJ; Ortega-Salas, RM; Peralbo-Santaella, E; Pérez-Gómez, JM; Sánchez-Sánchez, R; Solivera, J; Tena-Sempere, M; Toledano-Delgado, Á; Torres, E, 2023) |
| "Glioblastoma is a primary intracranial tumour with extremely high disability and fatality rates among adults." | ( Gao, M; Jiang, H; Liu, X; Wang, X; Ye, J; Zhang, D; Zhang, H; Zhao, S, 2023) |
| "Glioblastoma is the most common malignant brain tumor in adults." | ( Birkl-Toeglhofer, AM; Brawanski, KR; Freyschlag, CF; Haybaeck, J; Hoeftberger, R; Manzl, C; Sprung, S; Ströbel, T; Thomé, C, 2023) |
| "Glioblastoma is one of the most common and invasive types of primary brain malignancies in adults, accounting for 45." | ( Baghbanzadeh, A; Baradaran, B; Barpour, N; Doustvandi, MA; Javadrashid, D; Mohammadpour, ZJ; Mohammadzadeh, R, 2023) |
| "Glioblastomas are incurable tumors often associated with epileptic seizures." | ( Venkataramani, V, 2023) |
| "Glioblastoma is a refractory malignant tumor that requires novel therapeutic strategies for effective treatment." | ( Ando, S; Ii, H; Kojima, N; Moyama, C; Nakata, S; Nambu, H; Ohta, K, 2023) |
| "Glioblastoma is a malignant brain tumor with poor prognosis." | ( Cheng, Q; Dai, Z; Liang, X; Liu, Z; Luo, P; Wang, Z; Wen, Z; Zhang, H; Zhang, J; Zhang, M; Zhang, X, 2023) |
| "Glioblastoma is a highly malignant and invasive brain tumor, and there is an urgent need to establish a treatment option that prevents its growth and metastasis." | ( Nakao, S; Ohmori, S; Okamoto, K; Shimizu, T; Tsuchiya, N, 2023) |
| "Glioblastoma is the most aggressive primary brain tumor with an unmet need for more effective therapies." | ( Amit, I; Becher, B; Bühler, M; De Luca, R; Di Nitto, C; Hemmerle, T; Katzenelenbogen, Y; Kirschenbaum, D; Look, T; Neri, D; Puca, E; Ravazza, D; Rindlisbacher, L; Roth, P; Stucchi, R; Weiner, A; Weiss, T; Weller, M, 2023) |
| "Glioblastomas are highly aggressive and deadly brain tumours, with a median survival time of 14-18 months post-diagnosis." | ( Drill, M; Drummond, KJ; Galea, E; Hunn, M; Jayakrishnan, PC; Kan, LK; Monif, M; O'Brien, TJ; Sanfilippo, PG; Sequeira, RP; Todaro, M; Williams, DA, 2023) |
| "Glioblastoma is associated with low median survival time irrespective of maximal treatment." | ( Farzaneh, F; Jangholi, E; Kankam, SB; Khoshnevisan, A; Shafizadeh, M; Shafizadeh, Y, 2023) |
| "Glioblastoma is the most common and lethal brain tumor in adults." | ( Iturrioz-Rodríguez, N; Matheu, A; Sampron, N, 2023) |
| "Glioblastoma is associated with especially poor outcome in the elderly." | ( Harter, PN; Herms, J; Katzendobler, S; Niedermeyer, S; Niyazi, M; Stoecklein, VM; Thon, N; Tonn, JC; Trumm, C; Weller, J, 2023) |
| "Glioblastoma is the most aggressive form of brain tumor originating from glial cells with a maximum life expectancy of 14." | ( Afzal, M; Castresana, JS; Hasan, H; Shahi, MH, 2023) |
| "Glioblastoma is the most aggressive and fatal form of brain cancer." | ( Castresana, JS; Denizler-Ebiri, FN; Güven, M; Taşpınar, F; Taşpınar, M, 2023) |
| "Glioblastoma is the most common and deadly primary brain tumor in adults." | ( Craig, M; Fiset, B; Jenner, AL; Karimi, E; Quail, DF; Surendran, A; Walsh, LA, 2023) |
| "Glioblastomas are aggressive and usually incurable high-grade gliomas without adequate treatment." | ( Grujicic, D; Ilic, R; Isakovic, A; Karapandza, K; Martinovic, T; Raicevic, S; Stanojevic, Z; Tasic, J; Tomonjic, N; Vidicevic-Novakovic, S; Zekovic, J, 2023) |
| "Glioblastoma is a cranial malignant tumor with a high recurrence rate after surgery and a poor response to chemoradiotherapy." | ( Liang, X; Lin, H; Sheng, X; Zhou, X, 2023) |
| "Glioblastoma is one of the most common malignant brain tumors." | ( Chen, J; Cui, G; Gao, Z; Wang, X; You, YP; Yuan, R; Zhang, W, 2023) |
| "Glioblastomas are highly aggressive brain tumors for which therapeutic options are very limited." | ( Carson, SC; Colley, SB; Ingraham, CH; Jursic, BS; Lassak, A; Peruzzi, F; Rak, M; Reiss, K; Stalinska, J, 2023) |
| "Glioblastoma is the most frequent and practically incurable neoplasm of the central nervous system; thus, new treatment modalities have been investigated to find a solution more effective than the currently applied standards based on temozolomide." | ( Głowacka, P; Jaskólski, DJ; Pieczonka, AM; Pudlarz, A; Rachwalski, M; Świderska, E; Szemraj, J; Szymańska, J; Witusik-Perkowska, M; Zakrzewska, M, 2023) |
| "GBM (Glioblastoma) is the most lethal CNS (Central nervous system) tumor in adults, which inevitably develops resistance to standard treatments leading to recurrence and mortality." | ( Becker, AP; Becker, V; Bell, EH; Chakravarti, A; Cui, T; Fleming, JL; Grosu, AL; Han, C; Haque, SJ; Johnson, B; Kumar, A; Manring, HR; McElroy, J; Meng, X; Robe, PA; Schrock, MS; Sebastian, E; Showalter, CA; Singh, K; Summers, MK; Tong, ZY; Venere, M, 2023) |
| "Glioblastoma is the most common aggressive primary central nervous system cancer in adults characterised by uniformly poor survival." | ( Adda, L; Back, M; Bailey, DL; Barnes, EH; Coffey, R; De Abreu Lourenco, R; Ebert, M; Fitt, G; Foroudi, F; Francis, RJ; Gan, HK; Hicks, RJ; Khasraw, M; Koh, ES; Lasocki, A; Lau, E; Lee, ST; Leonard, R; Moffat, BA; Moore, A; Nowak, AK; Roach, P; Rosenthal, M; Scott, AM; Senko, C; Thomas, PA; Verhaak, R; Walsh, KM, 2023) |
| "Glioblastoma is a type of intracranial malignancy." | ( Maeoka, R; Matsuda, R; Morimoto, T; Nakagawa, I; Nakase, H; Nakazawa, T; Nishimura, F; Ouji, Y; Park, YS; Yamada, S; Yokoyama, S; Yoshikawa, M, 2023) |
| "Glioblastoma is one of the malignant tumors with poor prognosis and no effective treatment is available at present." | ( Chen, J; Shi, SS; Zhang, GL; Zhang, Q; Zheng, SX; Zhuang, BB, 2023) |
| "Glioblastoma is a severe brain tumor that requires aggressive treatment involving surgery, radiotherapy, and chemotherapy, offering a survival rate of only 15 months." | ( Bernardes Ferro, M; da Rosa, RG; da Silva, LF; de Oliveira, JVR; de Souza, BM; Henn, JG; Lopes Alves, GA; Morás, AM; Moura, DJ; Nugent, M; Pires Peña, F; Rapack Jacinto Silva, V; Silva Pinheiro, AC; Silveira Aguirre, TA; Steffens Reinhardt, L, 2023) |
| "Glioblastoma is the most common brain tumor, with high recurrence and low survival rates." | ( Chen, D; Chen, X; Feng, L; Han, F; Horimoto, K; Kawasaki, A; Kiboku, T; Li, Y; Sheng, G; Sun, M; Tang, Y; Wu, Z; Yao, K; Zhang, R; Zhang, Y, 2023) |
| "Glioblastoma is a severe brain tumor characterized by an extremely poor survival rate of patients." | ( Barilà, D; Borsellino, G; Cirotti, C; Contadini, C; De Bardi, M; Di Girolamo, C; Helmer-Citterich, M; Pepe, G; Taddei, I, 2024) |
| Excerpt | Reference |
|---|
| "Those treated for glioblastoma multiforme had a mean Karnofsky Performance Score of 86% (range 60-100%) at 1 month and 75% (range 60-100%) at 24 months." | ( Gutin, PH; Larson, DA; Leibel, SA; Levin, VA; Phillips, TL; Prados, MD; Silver, P; Sneed, PK; Wara, WM; Weaver, KA, 1991) |
| "A new radiotherapy schedule to treat glioblastoma multiforme after surgery, combining nicotinamide and carbogen." | ( Caciagli, P; Cartei, F; Colosimo, S; Danesi, R; Del Tacca, M; Ducci, F; Fatigante, L; Laddaga, M; Marini, C; Prediletto, R, 1997) |
| "We show that treatment of T98G glioblastoma cells with cisplatin but not the transplatin isomer activates JNK/SAPK about 10-fold." | ( Birrer, MJ; Bost, F; Gjerset, R; Haghighi, A; Liu, C; Mercola, D; Potapova, O, 1997) |
| "The outcome after treatment for glioblastoma remains poor." | ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998) |
| "A pilot protocol to treat recurrent glioblastoma was developed using fractionated stereotactic radiosurgery with concurrent intravenous (i." | ( Arbit, E; Lederman, G; Lombardi, E; Odaimi, M; Wronski, M; Wrzolek, M, 1998) |
| "Chemosensitivity of previously untreated glioblastomas to mitoxantrone, methotrexate, ACNU and BCNU was tested on cultured tissue." | ( Damian, MS; Leweke, F; Schachenmayr, W; Schindler, C, 1998) |
| "A pilot protocol to treat recurrent glioblastoma was developed using fractionated stereotactic radiosurgery with concurrent intravenous Taxol as a radiation sensitizer." | ( Arbit, E; Lederman, G; Lombardi, E; Odaimi, M; Wertheim, S, 1997) |
| "Twenty-three patients were treated (22 with glioblastoma multiforme and one with anaplastic astrocytoma)." | ( Ashley, DM; Bigner, DD; Cokgor, I; Colvin, OM; Dolan, ME; Ewesuedo, RB; Friedman, AH; Friedman, HS; Garcia-Turner, AM; Haglund, MM; Herndon, JE; Long, L; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, J; Stewart, ES; Tourt-Uhlig, S, 2000) |
| "Several protocols for the adjuvant treatment of glioblastoma multiforme (GBM) are currently being evaluated." | ( Deininger, MH; Grote, E; Meyermann, R; Wickboldt, J, 2000) |
| "In the treated glioblastoma patients, median disease-free interval was 28 months (range=9-59); median survival was 33." | ( Bartolomei, M; Caliceti, P; Chinol, M; De Cicco, C; Fiorenza, M; Gatti, M; Grana, C; Mazzetta, C; Paganelli, G; Robertson, C, 2002) |
| "Presently, there is no effective treatment for glioblastoma, the most malignant and common brain tumor." | ( Boudouresque, F; Brünner, N; Casellas, P; Chinot, O; Delfino, C; Dufour, H; Dussert, C; Fina, F; Grisoli, F; Martin, PM; Ouafik, L; Palmari, J; Sauze, S; Vuaroqueaux, V, 2002) |
| "In pretreated glioblastoma metabolic data of MRSI seem to be potentially helpful to differentiate tumorous and non tumorous enhancement phenomena after local immunotherapy, which might be useful for further treatment decisions." | ( Engelbrecht, V; Floeth, FW; Weber, F; Wittsack, HJ, 2002) |
| "Radiation dose escalation in the treatment of glioblastoma multiforme (GBM) may lead to improved disease control." | ( Douglas, JG; Hummel, S; Krohn, KA; Mankoff, DA; Rostomilly, R; Rostomily, RC; Scharnhorst, J; Silbergeld, DL; Spence, AM; Stelzer, KJ; Tralins, KS, 2002) |
| "For the treatment of glioblastoma multiforme, promising results are found in a Phase I trial with a median survival of 17." | ( Rodrigus, P, 2003) |
| "For the chemotherapeutical treatment of glioblastomas, the endothel cell is of special importance since due to its manifold metabolic and protective tasks within the blood-brain barrier, it already has a relatively high PGP expression under physiological conditions." | ( Harada, K; Rittierodt, M, 2003) |
| "Furthermore, treatment of fresh glioblastoma tissue from patients with PGZ, either alone or in combination with ATRA, induced a significant level of tumor cell apoptosis together with a downregulation of bcl-2 protein level as compared with untreated control brain tissue." | ( Black, KL; Elstner, E; Fenner, MH; Koeffler, HP; Liu, H; Posch, MG; Possinger, K; Stadelmann, C; von Deimling, A; Wächter, M; Zang, C, 2003) |
| "Conventional treatment of glioblastoma multiforme (GBM) cures less than 5% of patients." | ( Brachman, D; Buckner, J; Curran, WJ; Lustig, R; Mehta, MP; Okunieff, P; Podgorsak, EB; Sause, W; Schultz, CJ; Seiferheld, W; Souhami, L; Werner-Wasik, M; Zamorano, L, 2004) |
| "Standard treatment of glioblastoma multiforme consisting of surgical resection, radiation and/or chemotherapy is rarely curative, emphasizing the need for new chemotherapeutic drugs." | ( da Fonseca, CO; Fernandes, J; Gattass, CR; Teixeira, A, 2005) |
| "Radiation dose escalation in the treatment of glioblastoma multiforme may lead to improved disease control." | ( Douglas, JG; Krohn, KA; Mankoff, DA; Muzi, M; Rostomily, RC; Scharnhorst, J; Silbergeld, DL; Spence, AM; Stelzer, KJ; Tralins, KS, 2006) |
| "Although treatment of glioblastoma cells with the caspase inhibitor zVAD-fmk completely abolished AA-induced caspase activation, it did not significantly block AA-induced cell death." | ( Cardone, MH; Cho, CW; Choi, DS; Kim, CW; Rha, C; Sinskey, AJ, 2006) |
| "In all cell lines tested, treatment of glioblastoma multiforme cells with BCNU followed by AMD3100 results in synergistic antitumor efficacy in vitro." | ( Chan, JA; Kung, AL; Redjal, N; Segal, RA, 2006) |
| "Radiation therapy is a mainstay in the treatment of glioblastomas, but these tumors are often associated with radioresistance." | ( Fernandes, AM; Gupta, AK; Jiang, Z; Kao, GD; Maity, A, 2007) |
| "Thus, pretreatment of glioblastoma with an anti-inflammatory agent, either steroidal or non-steroidal, may compromise the action of a chemotherapeutic agent that mediates therapeutic action via oxidative stress." | ( Banik, NL; Das, A; Ray, SK, 2007) |
| "Our investigation revealed that treatment of glioblastoma T98G xenografts with the combination of ATRA and TXL induced differentiation and multiple molecular mechanisms for apoptosis." | ( Banik, NL; Karmakar, S; Patel, SJ; Ray, SK, 2007) |
| "In this report we demonstrate that treatment of glioblastoma cells with parthenolide resulted in rapid apoptosis through caspase 3/7 without a suppression of NF-kappaB activity." | ( Anderson, KN; Bejcek, BE, 2008) |
| "We show that treatment of glioblastoma cells, expressing constitutively activated Stat3, with the purified peptide aptamers strongly inhibits Stat3 signaling, causing cell growth arrest and inducing apoptosis." | ( Borghouts, C; Delis, N; Groner, B; Kunz, C, 2008) |
| "The multidisciplinary up to date treatment for glioblastoma patients combined maximal surgical removal of the tumor with postoperative radiotherapy and concomitant chemotherapy with temozolomide." | ( Kiss, R; Lefranc, F; Mijatovic, T, 2008) |
| "Temozolomide (TMZ) is used for treating glioblastoma." | ( Banik, NL; Das, A; Ray, SK, 2008) |
| "Current therapeutic goals for treatment of Glioblastoma Multiforme (GBM) involve gross total resection followed by multifractionated focal external beam radiation therapy (EBRT)." | ( Adler, JR; Jackson, PS; Lipani, JD; Sato, K; Soltys, SG, 2008) |
| "Lastly, the treatment of human glioblastoma multiforme orthotopic xenograft- bearing mice with nontoxic doses of narciclasine significantly increased their survival." | ( Berger, W; Debeir, O; Decaestecker, C; Kiss, R; Lamoral-Theys, D; Lefranc, F; Mathieu, V; Mégalizzi, V; Sauvage, S; Spiegl-Kreinecker, S; Van Goietsenoven, G, 2009) |
| "MSH6 mutations were confirmed in posttreatment TCGA glioblastomas but absent in matched pretreatment tumors." | ( Aldape, K; Cahill, DP; Iafrate, AJ; Louis, DN; Miao, J; Nutt, CL; Yip, S, 2009) |
| "Current standard therapy in the treatment of glioblastoma multiforme (GBM) is a combination of surgery, radiation, and chemotherapy using the drug temozolomide (TMZ)." | ( Bektas, M; Bigner, DD; Friedman, HS; Johnson, SP; Poe, WE, 2009) |
| "Following treatment of the glioblastoma cells with GHRH antagonists, nuclear translocation of apoptosis inducing factor (AIF) and Endonuclease G (Endo G) and the mitochondrial release of cytochrome c (cyt c) were detected, indicating that the cells were undergoing apoptosis." | ( Bellyei, S; Pozsgai, E; Schally, AV; Varga, JL; Vidaurre, I; Zarandi, M, 2010) |
| "A major barrier to progress in treatment of glioblastoma is the relative inaccessibility of tumors to chemotherapeutic agents." | ( Kumabe, T; Nishihara, M; Saito, R; Satoh, T; Sonoda, Y; Sugiyama, S; Tominaga, T; Yamashita, Y; Yokosawa, M; Yokoyama, M, 2010) |
| "Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy." | ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010) |
| "Finally, treatment of glioblastoma stem cells with TDZD-8 resulted in an inhibition of proliferation and self-renewal of these cells." | ( Aguilar-Morante, D; Garcia-Cabezas, MA; Morales-Garcia, JA; Perez-Castillo, A; Santos, A; Sanz-SanCristobal, M, 2010) |
| "Finally, Brefeldin-A treatment of glioblastoma cells led to Akt dephosphorylation; this effect was reversed when MT1-MMP was silenced." | ( Annabi, B; Pratt, J; Proulx-Bonneau, S, 2011) |
| "The new standard treatment of glioblastoma multiforme is concurrent radiotherapy (RT) and temozolomide." | ( Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S, 2012) |
| "As current treatments for glioblastoma commonly fail to cure, the need for more effective therapeutic options is overwhelming." | ( Halatsch, ME; Karpel-Massler, G; Kast, RE, 2011) |
| "In contrast, in vitro treatment of a glioblastoma cell line, BS-153, with endogenous EGFRwt amplification and EGFRvIII expression resulted not only in dephosphorylation of the EGFR, but also of key regulators in the pathway such as AKT." | ( Bady, P; Delorenzi, M; Diserens, AC; Frei, K; Hamou, MF; Hegi, ME; Heppner, FL; Hofer, S; Kamoshima, Y; Koch, A; Kouwenhoven, MC; Lambiv, WL; Mariani, L; Matter, MS; Merlo, A; Yonekawa, Y, 2011) |
| "For an efficient treatment of glioblastomas it is necessary to deliver anti-cancer drugs across the intact BBB." | ( Bernreuther, C; Gelperina, S; Glatzel, M; Khalansky, AS; Kreuter, J; Maksimenko, O; Wohlfart, S, 2011) |
| "Specifically, treatment of glioblastoma cell lines with β-elemene attenuated phosphorylation of multiple members of the kinase families in the Ras/Raf/MEK/ERK cascade, including Raf-1 and ERK as well as downstream signaling targets such as Bcl-2." | ( Chen, YW; Wang, W; Wei, ZQ; Wu, CM; Xu, YH; Yao, YQ; Zhao, YS; Zhu, TZ, 2012) |
| "Standard treatment for glioblastoma multiforme (GBM) changed in 2005 when addition of temozolomide (TMZ) to maximal surgical resection followed by radiation therapy (RT) was shown to prolong survival in a clinical trial." | ( Abrams, J; Harlan, L; Mann, B; Yabroff, KR; Zeruto, C, 2012) |
| "Carmustine is used in the treatment of glioblastomas as locally applied chemotherapy in the form of biodegradable wafers, which are lined on the walls of the resection cavity at the end of the resection, to increase local concentrations and decrease systemic toxicity." | ( Dörner, L; Kesari, S; Mehdorn, HM; Nabavi, A; Schultka, S; Spalek, K; Ulmer, S, 2012) |
| "Recent preclinical studies suggest that treating glioblastoma (GBM) with a combination of targeted chemotherapy and radiotherapy may enhance the anti-tumor effects of both therapies." | ( Bruce, JN; Canoll, P; Christensen, JG; Crisman, C; D'Amico, R; Ebiana, V; Gil, O; Kennedy, BC; Lei, L; Rosenfeld, SS; Sisti, J, 2012) |
| "The efficacy of treatment for glioblastoma multiforme is currently limited by the development of resistance, particularly, but not exclusively, due to the expression of the DNA repair enzyme O6-methylguanine methyltransferase (MGMT) in a significant proportion of astrocytic tumors." | ( Hatzidaki, E; Koukoulis, GK; Papandreou, CN; Stathakis, NE; Vlachostergios, PJ, 2013) |
| "For the treatment of glioblastoma multiforme, an "anticancer drug cocktail" delivered by biodegradable poly-lactide-co-glycolide (PLGA)-microspheres is proposed." | ( Allhenn, D; Béduneau, A; Lamprecht, A; Neumann, D; Pellequer, Y, 2013) |
| "Anti-angiogenic treatment of glioblastoma with Vascular Endothelial Growth Factor (VEGF)- or VEGF Receptor 2 (VEGFR2) inhibitors normalizes tumor vessels, resulting in a profound radiologic response and improved quality of life." | ( Bourgonje, A; Heerschap, A; Hendriks, W; Leenders, WP; Navis, AC; van der Laak, JA; Verrijp, K; Wesseling, P; Wright, A, 2013) |
| "The upfront approach to treatment of glioblastoma in the unresectable population warrants further investigation in randomized controlled phase III trials." | ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; Peters, KB; Reardon, DA; Sumrall, AL; Turner, S; Vredenburgh, JJ, 2013) |
| "There have been few advances in the treatment of glioblastoma multiforme in the past 40 years beyond surgery, radiotherapy, chemotherapy, and corticosteroids." | ( Amos, A; Bost, J; Maroon, J; Zuccoli, G, 2013) |
| "The current standard treatment of glioblastoma includes maximal safe surgical resection, radiation, and temozolomide." | ( Chen, SE; Choi, SS; De Groot, JF; Lei, X; Rogers, JE, 2014) |
| "Then, we treated glioblastoma cell lines (U87 and U251) with 5-aza-2-deoxycytidines (5-aza-dC) and detected cell biological behaviors." | ( Bai, Y; Bao, ZS; Chen, Y; Wang, LJ; Yan, ZH; Zhang, QG; Zhang, W, 2013) |
| "The standard adjuvant treatment for glioblastoma is temozolomide concomitant with radiotherapy, followed by a further six cycles of temozolomide." | ( Arranz, JL; Balañá, C; Benavides, M; Bugés, C; Cano, JM; de la Peñas, R; García-Bueno, JM; Gil, M; Lopez, D; Martin, JM; Molina-Garrido, MJ; Perez-Segura, P; Rodriguez, A; Sanz, SM; Sepúlveda, JM; Vaz, MA, 2014) |
| "Standard treatment for glioblastoma (GBM) is surgery followed by radiation (RT) and temozolomide (TMZ)." | ( Camphausen, K; Fine, HA; Ho, J; Iwamoto, F; Kim, L; Krauze, A; Kreisl, T; McNeil, K; Ning, H; Ondos, J; Shankavaram, U; Smith, S; Sul, J, 2013) |
| "Despite improved treatment options, glioblastoma multiforme (GBM) remains the most aggressive brain tumour with the shortest post-diagnostic survival." | ( Bjerkvig, R; Huszthy, PC; Lah Turnšek, T; Motaln, H; Primon, M; Talasila, KM; Torkar, A, 2013) |
| "Many physicians are reluctant to treat elderly glioblastoma (GBM) patients as aggressively as younger patients, which is not evidence based due to the absence of validated data from primary studies." | ( Cheng, JX; Dong, Y; Han, N; Liu, BL; Yin, AA; Zhang, LH; Zhang, X, 2013) |
| "Pseudoprogression (PP) during adjuvant treatment of glioblastoma (GBM) is frequent and is a clinically and radiologically challenging problem." | ( Cerhova, J; Chakravarti, A; Engellandt, K; Geiger, KD; Juratli, TA; Krex, D; Lautenschlaeger, T; Schackert, G; von Kummer, R, 2013) |
| "radiotherapy for treating glioblastoma (GBM), Medline, Current Contents, and Cochrane database were searched." | ( Lin, ZX; Yang, LJ; Zhou, CF, 2014) |
| "We analyzed the data of 210 patients treated for glioblastoma between 2005 and 2013." | ( Bagó, A; Bajcsay, A; Fedorcsák, I; Kásler, M; Lövey, J; Mangel, L; Sipos, L, 2013) |
| "Developing an effective drug for treating human glioblastoma multiform (GBM) has been investigated persistently." | ( Chan, TM; Chiou, TW; Chou, CW; Chuang, CH; Harn, HJ; Harn, YW; Ho, LI; Huang, MH; Lin, PC; Lin, SZ; Su, HL, 2014) |
| "With standard treatment for glioblastoma (GBM) consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is ~14." | ( Chung, C; Jiang, H; Laperriere, N; Lwin, Z; Mason, WP; McNamara, MG; Millar, BA; Sahgal, A, 2014) |
| "Patients undergoing treatment for glioblastoma multiforme are routinely placed on prophylactic treatment for Pneumocystis jirovecii pneumonia because of significant therapy-induced lymphopenia." | ( Harmon, M; Lesser, GJ; Lewis, JA; Owen, J; Peacock, JE; Petty, WJ; Pirmohamed, M; Valente, K, 2015) |
| "Temozolomide (TMZ) is widely used to treat glioblastoma multiforme (GBM)." | ( Bekar, A; Berghoff, AS; Budak, F; Cecener, G; Egeli, U; Kocaeli, H; Preusser, M; Ricken, G; Taskapılıoglu, MO; Tezcan, G; Tolunay, S; Tunca, B, 2014) |
| "Although the optimal treatment of frail glioblastoma patients is still controversial, previous randomized trials have excluded such patients." | ( Choi, SH; Han, TJ; Kim, IH; Kim, TM; Lee, SH; Lim, YJ; Paek, SH; Park, CK; Park, SH, 2015) |
| "optimal treatment of glioblastoma (gBM) in the elderly remains unclear." | ( Al-Zahrani, A; Coate, L; Laperriere, N; Lwin, Z; Macfadden, D; Mason, WP; Massey, C; McNamara, MG; Menard, C; Millar, BA; Sahgal, A, 2014) |
| "Drug resistance is a major issue in the treatment of glioblastoma." | ( Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Raktoe, RS; Vandertop, WP; Wesseling, P; Wurdinger, T, 2014) |
| "The first-line treatment of glioblastoma typically consists of a maximal surgical resection, followed by a combination of radio-chemotherapy with temozolomide." | ( Belzile, F; Fortin, D; Mathieu, D; Morin, PA; Paré, FM, 2014) |
| "Similarly, treatment of glioblastoma cells with the synthetic glucocorticoid dexamethasone led to a reduction of TDO expression and activity in vitro and in vivo." | ( Blaes, J; Bunse, L; Litzenburger, UM; Ochs, K; Opitz, CA; Ott, M; Platten, M; Pusch, S; Rauschenbach, KJ; Sahm, F; von Deimling, A; Wick, W, 2015) |
| "Non-invasive monitoring of response to treatment of glioblastoma (GB) is nowadays carried out using MRI." | ( Arús, C; Candiota, AP; Delgado-Goñi, T; Julià-Sapé, M; Pumarola, M, 2014) |
| "Standard treatment for glioblastoma comprises surgical resection, chemotherapy with temozolomide, and radiotherapy." | ( Ham, Y; Jin, J; Joo, KM; Kang, W; Kim, S; Nam, DH; Woo, SR; Yang, H, 2014) |
| "Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)-targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf)." | ( Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S, 2014) |
| "Chemotherapy is an adjuvant treatment for glioblastomas, however, chemotherapy remains palliative because of the development of multidrug resistance (MDR)." | ( Allender, E; Hayes, E; Ichi, S; Lewis, R; Mania-Farnell, B; Mayanil, CS; Shim, K; Takao, T; Tomita, T; Xi, G, 2016) |
| "Despite multimodal treatment, glioblastoma (GBM) therapy with temozolomide (TMZ) remains inefficient due to chemoresistance." | ( Bartsch, JW; Biniossek, ML; Carl, B; Conrad, C; Culmsee, C; Dolga, AM; Dong, F; Eibach, M; Koller, G; Nimsky, C; Schieber, S; Schilling, O; Schlomann, U; Strik, H, 2015) |
| "Temozolomide (TMZ) is widely used for treating glioblastoma (GBM), which can effectively inhibit the GBM growth for some months; however, it still could not prevent the invariable recurrence of GBM." | ( Fei, X; Shi, L; Wang, Z, 2015) |
| "The current standard treatment for glioblastoma multiforme (GBM) is surgery followed by chemotherapy and external radiation." | ( Chung, LK; Gopen, Q; Kamei, DT; Nagasawa, DT; Pelargos, PE; Tenn, S; Ung, N; Voth, B; Yang, I, 2015) |
| "Two independent temozolomide-treated glioblastoma cohorts-one Australian (Australian Genomics and Clinical Outcomes of Glioma, n = 163) and the other American (University of California Los Angeles/Kaiser Permanente Los Angeles, n = 159)-were studied." | ( Cloughesy, TF; Ha, W; Hitchins, MP; Lai, A; McDonald, KL; Nguyen, HN; Nowak, AK; Rapkins, RW; Wang, F, 2015) |
| "The standard treatment for glioblastoma multiforme (GBM) remains maximal safe surgical resection." | ( de Boer, E; Gillespie, GY; Hartman, Y; Korb, M; Kovar, J; Markert, JM; Rosenthal, EL; Warram, JM, 2015) |
| "Temozolomide (TMZ) is widely used for treating glioblastoma (GBM), which can effectively inhibit the GBM growth for some months; however, it still cannot prevent the invariable recurrence of GBM." | ( Shi, L; Sun, G, 2015) |
| "In the effort to find better treatments for glioblastoma we tested several currently marketed non-chemotherapy drugs for their ability to enhance the standard cytotoxic drug currently used to treat glioblastoma- temozolomide." | ( Coveñas, R; Kast, RE; Lladó, S; Muñoz, M; Ramiro, S; Toro, S, 2016) |
| "Context Since methods utilised in the treatment of glioblastoma multiforme (GBM) are inadequate and have too many side effects, usage of herbal products in the treatment process comes into prominence." | ( Aslan, A; Emsen, B; Togar, B; Turkez, H, 2016) |
| "To enhance the benefit of TMZ in the treatment of glioblastomas, effective combination strategies are needed to sensitize glioblastoma cells to TMZ." | ( Dai, S; Gong, Z; Qian, L; Sun, L; Xu, Z; Yan, Y, 2016) |
| "There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)." | ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016) |
| "The oncology focus is for the treatment of glioblastoma, where it has received orphan designation by the US Food and Drug Administration, and prostate cancer." | ( Weinberg, MA, 2016) |
| "Moreover, treatment of glioblastoma cells with salinomycin, an ER stress-inducing drug, and temozolomide resulted in enhanced DNA damage and a synergistic antitumor effect in vitro." | ( Acanda, AM; Alonso, MM; Aragón, T; Fueyo, J; Garzón, AG; Gomez-Manzano, C; Gonzalez-Huarriz, M; Idoate, MA; Jones, C; Lang, FF; Martínez-Irujo, JJ; Martínez-Velez, N; Vera, B; Xipell, E, 2016) |
| "Prior targeted treatment for glioblastoma multiforme (GBM) with anti-angiogenic agents, such as bevacizumab, has been met with limited success potentially owing to GBM tumor's ability to develop a hypoxia-induced escape mechanism--a glycolytic switch from oxidative phosphorylation to glycolysis, an old concept known as the Warburg effect." | ( Asuthkar, S; Guda, MR; Tsung, AJ; Velpula, KK; Yuen, CA, 2016) |
| "We found that treating glioblastoma (GBM) tumors with siRNA against VDAC1, a mitochondrial protein found at the crossroads of metabolic and survival pathways and involved in apoptosis, inhibited tumor growth while leading to differentiation of tumor cells into neuronal-like cells, as reflected in the expression of specific markers." | ( Arif, T; Krelin, Y; Shoshan-Barmatz, V, 2016) |
| "We show that treatment of human glioblastoma multiforme (GBM) tumour cells with imatinib and the closely-related drug, nilotinib, strikingly increases tyrosine phosphorylation of p130Cas, focal adhesion kinase (FAK) and the downstream adaptor protein paxillin (PXN), resulting in enhanced cell migration and invasion." | ( Barrett, A; Brandner, S; Evans, IM; Frankel, P; Frolov, A; Li, N; Lockwood, N; Paliashvili, K; Sidlauskas, K; Zachary, IC, 2016) |
| "Thirty-nine patients after the standard treatment of a glioblastoma underwent advanced imaging by MRS and ADC at the time of suspected recurrence - median time to progression was 6." | ( Bulik, M; Jancalek, R; Kazda, T; Lakomy, R; Pospisil, P; Slampa, P; Smrcka, M, 2016) |
| "LP resveratrol-treated glioblastomas showed less Cyclin D1 staining, enhanced autophagy with up-regulated LC3 and Beclin1 expression, and widely distributed apoptotic foci around tumor capillaries with suppressed STAT3 expression and nuclear translocation." | ( Hong, L; Jia, L; Jia-Yao, G; Jie, B; Li-Li, W; Lin, S; Mo-Li, W; Pei-Nan, L; Peng, Z; Qian, W; Qing-You, K; Shun, S; Xiao-Hong, S; Xiao-Yan, C; Xue, S, 2016) |
| "Five patients were treated cases of glioblastoma with suspected recurrence." | ( Anees K, M; Jayaprakash, PG; Joy, A; Madhavan, J; Nair, S; Nanabala, R; Pillai, MR; Sasikumar, A, 2017) |
| "In five treated cases of glioblastoma with suspected recurrence the findings of Ga PSMA-11 PET/CT showed good correlation with that of F-FDG PET/CT scan." | ( Anees K, M; Jayaprakash, PG; Joy, A; Madhavan, J; Nair, S; Nanabala, R; Pillai, MR; Sasikumar, A, 2017) |
| "Bevacizumab (BV) has been used to treat recurrent glioblastoma with a progression free survival of approximately 3-3." | ( Boockvar, JA; Burkhardt, JK; Chakraborty, S; Filippi, CG; Fralin, S; Langer, DJ; Ortiz, R; Ray, A; Wong, T, 2016) |
| "Antiangiogenic treatment of glioblastomas with Bevacizumab lacks predictive markers." | ( Bähr, O; Hattingen, E; Pilatus, U; Ronellenfitsch, MW; Steidl, E; Steinbach, JP; Zanella, F, 2016) |
| "This study aimed to improve the treatment of glioblastoma (GBM), the most common brain cancer, by testing whether the efficacy of the DNA alkylator temozolomide (TMZ) varies with the time of its administration." | ( Binz, A; Herzog, ED; Kfoury, N; Kim, A; Marpegan, L; Rubin, JB; Simon, T; Slat, EA; Sponagel, J, 2017) |
| "In this study, we show that treatment of glioblastoma cells with 17-AAG leads to HSP90 inhibition indicated by loss of stability of the EGFR client protein, and significant increase in HSP70 expression." | ( Guerra, B; Schaefer, S; Svenstrup, TH, 2017) |
| "The current treatment of glioblastoma multiforme (GBM) is limited by the restricted arsenal of agents which effectively cross the blood brain barrier (BBB)." | ( Adhikari, B; Akers, J; Brandel, MG; Carter, BS; Chen, CC; Deming, T; Futalan, D; Li, J, 2017) |
| "Targeted approaches for treating glioblastoma (GBM) attempted to date have consistently failed, highlighting the imperative for treatment strategies that operate on different mechanistic principles." | ( Chang, JH; Choi, J; Kang, JH; Kang, SG; Kim, SY; Park, J; Shim, JK, 2018) |
| "The optimal treatment of glioblastoma multiforme (GBM) in patients aged ≥70 years with a Karnofsky performance status (KPS) <70 is not established." | ( Barrie, M; Barrière, J; Beauchesne, P; Benouaich-Amiel, A; Campello, C; Cartalat-Carel, S; Catry-Thomas, I; Chinot, OL; Delattre, JY; Fabbro, M; Frappaz, D; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Le Rhun, E; Mokhtari, K; Reyes-Botero, G; Taillandier, L; Tanguy, ML; Tennevet, I, 2018) |
| "Despite continuous improvements in treatment of glioblastoma, tumor recurrence and therapy resistance still occur in a high proportion of patients." | ( Castera, L; Chevalier, F; Chneiweiss, H; El-Habr, EA; Junier, MP; Lesueur, P; Müller, E; Saintigny, Y; Stefan, D, 2018) |
| "Fifty-two patients with untreated glioblastoma (isocitrate dehydrogenase 1 wild type [IDH1wt]) were examined with a physiological MRI protocol including a multiparametric quantitative blood oxygen level dependent (qBOLD) approach and vascular architecture mapping (VAM)." | ( Buchfelder, M; Coras, R; Doerfler, A; Kitzwögerer, M; Oberndorfer, S; Roessler, K; Stadlbauer, A; Zimmermann, M, 2018) |
| "The approach to treat glioblastoma has not suffered major changes over the last decade and temozolomide (TMZ) remains the mainstay for chemotherapy." | ( Basso, J; Miranda, A; Pais, A; Sousa, J; Vitorino, C, 2018) |
| "An effective treatment for glioblastoma is needed." | ( Chen, Y; Cheng, YC; Chiu, CY; Kan, PC; Tsao, MJ, 2018) |
| "Ten patients were treated cases of glioblastoma with suspected recurrence." | ( Bhattacharya, P; Charan Patro, K; Joy, A; Kashyap, R; Oommen, KE; Pillai, MRA; Reddy Pilaka, VK; Sasikumar, A, 2018) |
| "Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade, but its treatment benefits are limited by acquired resistance, a process that remains incompletely understood." | ( Chen, X; Fang, D; Gan, H; Giannini, C; He, L; Hu, Z; Kitange, GJ; Lee, JH; Meyer, FB; Parney, IF; Sarkaria, JN; Wang, H; Zhang, M; Zhang, Z, 2018) |
| "Current multimodal treatments for glioblastoma minimally increase life expectancy, but significant advancements in prognosis have not been made in the past few decades." | ( Lee, C; Robinson, M; Willerth, SM, 2018) |
| "The difficulty in treating glioblastoma is largely attributed to the lack of effective therapeutic targets." | ( Guo, S; Kelly, DF; Liang, Y; Murphy, S; Pham, L; Pridham, KJ; Sheng, Z; Varghese, RT; Young, S, 2018) |
| "Poor response to current treatments for glioblastoma has been attributed to the presence of glioblastoma stem-like cells (GSCs)." | ( Arriagada, V; Carrasco, C; Erices, JI; Niechi, I; Oyarzún, C; Quezada, C; Rocha, JD; Toro, MLÁ; Torres, Á, 2018) |
| "Therapeutic options for the treatment of glioblastoma remain inadequate despite concerted research efforts in drug development." | ( Abdelmoula, WM; Agar, JN; Agar, NYR; Calligaris, D; Carlson, BL; Elmquist, WF; Emdal, KB; Gupta, SK; Jackson, PR; Johnson, AJ; Joughin, BA; Kellersberger, KA; Kim, M; Kolluri, A; Laramy, JK; Lauffenburger, DA; Lu, FK; Mladek, AC; Peng, S; Randall, EC; Reddy, RJ; Regan, MS; Roos, A; Sarkaria, JN; Swanson, KR; Tran, NL; White, FM; Xie, XS, 2018) |
| "Temozolomide (TMZ) is the first-line treatment for Glioblastoma Multiforme (GBM)." | ( Andrade, S; Coelho, MÁN; Loureiro, JA; Pereira, MC; Ramalho, MJ, 2019) |
| "Standard-of-care treatment of glioblastomas involves maximal safe resection and adjuvant temozolomide chemo-radiotherapy." | ( Chan, DTM; Chan, KY; Ho, JMK; Lam, SW; Lee, MWY; Mak, CHK; Poon, WS; Tse, TPK; Wong, ST; Woo, PYM, 2019) |
| "The aim of the present study was to treat glioblastoma cells with a selective HDAC6 inhibitor, tubastatin A, to determine if the malignant phenotype may be reverted." | ( Castresana, JS; Erausquin, E; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A, 2019) |
| "Long‑term local treatment of glioblastoma is rarely achieved and the majority of the patients undergo relapse." | ( Bureta, C; Komiya, S; Maeda, S; Nagano, S; Saitoh, Y; Sasaki, H; Setoguchi, T; Taniguchi, N; Tokumoto, H, 2019) |
| "In this work, we have chronically treated U251 glioblastoma cells with low, physiologically realistic concentrations, of EGCG, in order to investigate its effects both on telomeres and on genome integrity." | ( Marinaccio, J; Sgura, A; Udroiu, I, 2019) |
| "Considering carnosine for the treatment of glioblastoma, we investigated which proton-coupled oligopeptide transporters (POTs) are present in glioblastoma cells and how they contribute to the uptake of carnosine." | ( Birkemeyer, C; Gaunitz, F; Heinrich, M; Meixensberger, J; Oppermann, H, 2019) |
| "Current treatments for glioblastoma have failed to significantly increase patient survival, are extremely cytotoxic, can cause severe side effects, and are ineffective." | ( Jones, T; Major, S; Webb, A; Zhang, B, 2020) |
| "The therapeutic treatment of glioblastoma multiforme (GBM) remains a major challenge." | ( Hua, L; Li, S; Liang, J; Liu, H; Xu, Q; Ye, C; Yu, R; Zhao, L, 2019) |
| "Therapeutic options to treat primary glioblastoma (GBM) tumors are scarce." | ( Chen, JE; Harley, BAC; Laken, SE; Pedron, S; Sarkaria, JN; Wolter, GL, 2019) |
| "Standard treatment for glioblastoma (GBM) patients is surgery and radiochemotherapy (RCT) with temozolomide (TMZ)." | ( Åkesson, L; Bratthäll, C; Broholm, H; Fomichov, V; Green, H; Grunnet, K; Hallbeck, M; Jakobsen, I; Malmström, A; Milos, P; Mudaisi, M; Papagiannopoulou, A; Poulsen, HS; Söderkvist, P; Stenmark-Askmalm, M; Strandeus, M; Łysiak, M, 2020) |
| "Temozolomide is the current first-line treatment for glioblastoma patients but, because many patients are resistant to it, there is an urgent need to develop antitumor agents to treat temozolomide-resistant glioblastoma." | ( Jang, H; Jeon, JH; Kang, SG; Kang, SW; Kim, DK; Kim, HY; Kim, SY; Lee, BI; Shim, JK, 2019) |
| "Current treatment against glioblastoma consists of surgical resection followed by temozolomide, with or without combined radiotherapy." | ( Castresana, JS; De La Rosa, J; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A; Zazpe, I; Zelaya, MV, 2020) |
| "One of the major challenges in treatment of glioblastoma is drug resistance." | ( Khathayer, F; Ray, SK; Taylor, MA, 2020) |
| "New approaches to treatment of glioblastoma, such as targeting metabolism, have been studied." | ( Hirose, Y; Ohba, S, 2020) |
| "We investigated a potential treatment for glioblastoma that targets the amino acid metabolism." | ( Hirose, Y; Ohba, S, 2020) |
| "Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate." | ( Alonso, M; Balana, C; Berrocal, A; Carrato, C; Covela, M; de Las Peñas, R; Del Barco, S; Domenech, M; Esteve, A; Estival, A; Fuster, J; Gallego, O; Gil-Gil, M; Gironés, R; Herrero, A; Luque, R; Manuel Sepúlveda, J; Martinez-García, M; Mesia, C; Munne, N; Muñoz-Langa, J; Navarro, LM; Olier, C; Peralta, S; Perez-Martín, FJ; Perez-Segura, P; Pineda, E; Sanz, C; Vaz, MA; Villa, S, 2020) |
| "The challenge in the treatment of glioblastoma is the failure to identify the cancer invasive area outside the contrast-enhancing tumour which leads to the high local progression rate." | ( Boonzaier, NR; Li, C; Matys, T; Price, SJ; van der Hoorn, A; Yan, JL, 2020) |
| "Cyclopamine potentiated temozolomide treatment in glioblastoma cell lines by inducing apoptosis through activation of caspase-3 cleaved." | ( Arrais-Neto, AM; Carballo, GB; Matias, D; Pessoa, LS; Ribeiro, JH; Spohr, TCLSE, 2020) |
| "The major difficulty in treating glioblastoma stems from the intrinsic privileged nature of the brain." | ( Abrams, M; Anderson, T; Boockvar, JA; D'Amico, R; Faltings, L; Filippi, CG; Fralin, S; Khatri, D; Langer, DJ; Li, M; Patel, NV; Ratzon, F; Reichman, N; Wong, T, 2020) |
| "Temozolomide (TMZ) is widely used for treating glioblastoma multiforme (GBM), however, the treatment of such brain tumors remains a challenge due to the development of resistance." | ( Baek, ST; Hsieh, JT; Kim, S; Yun, EJ, 2020) |
| "Although treatment for glioblastoma has progressed rapidly, novel targets for glioblastoma are insufficient, particularly those used in precision medicine." | ( Ji, X; Jia, WY; Liu, GM; Lu, TC; Luo, YG; Sun, ML, 2020) |
| "Temozolomide is the first line of treatment for glioblastoma, one of the most aggressive brain tumors that remains incurable despite advancements with treatment modalities." | ( Gjika, E; Keidar, M; Kirschner, ME; Lin, L; Pal-Ghosh, S; Sherman, JH; Stepp, MA, 2020) |
| "Current treatments for glioblastoma patients consist of surgery followed by radiation in combination with temozolomide." | ( Alexandru, O; Artene, SA; Danoiu, S; Dricu, A; Elena Cioc, C; Horescu, C; Sevastre, AS; Stefana Oana, P; Tache, DE; Tuta, C, 2020) |
| "After generating a number of treatment resistant Glioblastoma cell lines we observed that resistant cell lines lacked EGFR activation and expression." | ( Areeb, Z; Gomez, J; Jones, J; Kaye, AH; Luwor, RB; Morokoff, AP; Nguyen, HPT; Paradiso, L; Stuart, SF; West, AJ; Zulkifli, A, 2020) |
| "Radiographic monitoring of posttreatment glioblastoma is important for clinical trials and determining next steps in management." | ( Chiang, GC; Ebani, EJ; Meng, A; Strauss, SB, 2021) |
| "Current standard-of-care treatment for glioblastoma, the most common malignant primary central nervous system (CNS) tumor, consists of surgical resection followed by adjuvant chemotherapy and radiation (Stupp protocol), providing an overall median survival of 15 months." | ( Mittal, S; Walker, BC, 2020) |
| "The standard of care treatment for glioblastoma is surgical resection followed by radiotherapy to 60 Gy with concurrent and adjuvant temozolomide with or without tumor-treating fields." | ( Kotecha, R; Mehta, MP; Tom, MC, 2021) |
| "Successful treatment of glioblastoma (GBM) is hampered by primary tumor recurrence after surgical resection and poor prognosis, despite adjuvant radiotherapy and chemotherapy." | ( Bouché, M; Burdick, JA; Chen, MH; Cormode, DP; Dong, YC; Dorsey, J; Hsu, JC; Salinas, RD; Saxena, D; Sheikh, S; Song, H; Taing, K, 2021) |
| "The difficulty in treatment of glioblastoma is a consequence of its natural infiltrative growth and the existence of a population of therapy-resistant glioma cells that contribute to growth and recurrence." | ( Hooper, DC; Kenyon, LC; Prosniak, M, 2021) |
| "Key Words: Bevacizumab, Duration of treatment, Glioblastoma multiforme, Predictive score, Temozolomide." | ( Besiroglu, M; Demir, T; Shbair, ATM; Topcu, A; Turk, HM; Yasin, AI, 2021) |
| "Moreover, xyloketal B treatment induces glioblastoma cell death." | ( Bandura, J; Feng, ZP; Gong, H; Sun, HS; Wang, GL, 2022) |
| "Temozolomide is used in first-line treatment for glioblastoma." | ( Heng, X; Peng, S; Song, Q; Sun, Z; Zhu, X, 2021) |
| "Thus, RDT is expected to enhance RT treatment of glioblastoma without severe toxicity under clinically feasible conditions." | ( Doi, M; Ikemoto, MJ; Iwahashi, H; Nagasawa, S; Narita, Y; Takahashi, J; Takahashi, M; Yamamoto, J, 2021) |
| "The non-invasive treatment of glioblastoma (GBM) is of great significance and can greatly reduce the complications of craniotomy." | ( Lee, CS; Liu, W; Wang, P; Wu, J; Zhang, C; Zhang, W; Zheng, X, 2021) |
| "Standard treatment of glioblastoma consisting of maximal safe resection, adjuvant radiotherapy and chemotherapy with temozolomide, results in an overall median survival of 14." | ( Burgess, C; FitzJohn, T; Kaye, AH; O'Rawe, M; Pandey, R; Sim, D; Tan, ST; Wickremesekera, AC; Young, D, 2022) |
| "The standard treatment of glioblastoma patients consists of surgery followed by normofractionated radiotherapy (NFRT) with concomitant and adjuvant temozolomide chemotherapy." | ( Ehret, F; Grosu, AL; Kaul, D; Klement, RJ; Lewitzki, V; Polat, B; Popp, I; Sweeney, RA, 2022) |
| "Currently, there are no effective treatments for glioblastoma." | ( Chen, J; Liang, RS; Liu, S; Wang, CH; Zhang, Q; Zhuang, BB; Zhuang, YD, 2022) |
| "In this study, we treated glioblastoma cells with RSL3, a ferroptosis inducer, in vitro (cell lines) and in vivo (subcutaneous and orthotopic animal models)." | ( Bian, XW; Cai, XW; Cao, MF; Gai, QJ; He, J; He, MM; Leng, P; Lu, HM; Mao, M; Qin, Y; Wang, C; Wang, Y; Wang, YX; Wen, XM; Yang, FC; Yao, XH; Yao, XX; Zhu, J, 2022) |
| "Temozolomide is drug of choice for the treatment of glioblastoma, but dose-related side effects limit its use." | ( Ali, J; Baboota, S; Mittal, S, 2022) |
| "The standard treatment for glioblastoma (GB) is maximal surgical resection combined with radiotherapy and chemotherapy." | ( Chang, J; Guo, J; Hou, S; Li, B; Li, S; Wen, C; Xiao, J; Xu, Y; Yan, X; Zhang, H, 2022) |
| "The standard treatment for glioblastoma is maximal surgical resection followed by postoperative temozolomide administration combined with radiation therapy." | ( Imai, R; Sasaki, H, 2022) |
| "Current standards for the treatment of glioblastoma include a combination of surgical, radiation, and drug therapy methods." | ( Alyautdin, R; Chubarev, V; Grigorevskikh, E; Ismail, N; Merkulov, V; Petrenko, D; Smolyarchuk, E; Sologova, S; Syzrantsev, N, 2022) |
| "The effective treatment of glioblastoma (GBM) is a great challenge because of the blood-brain barrier (BBB) and the growing resistance to single-agent therapeutics." | ( Chai, T; Du, Q; Hanif, S; Ismail, M; Li, Y; Muhammad, P; Shi, B; Yang, W; Zhang, D; Zheng, M, 2022) |
| "Accurate diagnosis and highly effective treatment of glioblastoma are still challenges in clinic." | ( Cao, Y; Gao, W; Jin, L; Lv, Z; Wang, Y; Xue, D; Yin, N; Zhang, H; Zhang, T, 2022) |
| "Furthermore, miR-147a mimic-treated human glioblastoma cells exhibited higher sensitivity to TMZ chemotherapy than those treated with the mimic control in vitro." | ( Ge, FH; Hao, RR; Li, WX; Shen, JL; Wang, XL; Xu, AB; Xu, P; Xu, Z, 2022) |
| "After surgical treatment, glioblastoma (GBM) patients require prompt therapy within 14 days in a patient-specific manner." | ( Baek, S; Chang, JH; Choi, RJ; Jo, E; Kang, SG; Kim, EH; Lee, D; Lee, JB; Moon, JH; Park, J; Park, JS; Shim, JK; Sung, HJ; Yoon, SJ; Yu, SE, 2022) |
| "The standard treatment for glioblastoma is 6 weeks of radiation therapy and daily temozolomide." | ( Hundal, J; Pereira, MK; Singh, A; Vredenburg, J, 2023) |
| "The standard treatment for glioblastoma is 6 weeks of radiation therapy and daily temozolomide." | ( Hundal, J; Pereira, MK; Singh, A; Vredenburg, J, 2023) |
| "The presence of VM greatly hinders the treatment of glioblastoma (GBM) with anti-angiogenic drugs." | ( Dong, W; Liu, L; Liu, M; Liu, X; Ruan, X; Wang, D; Wang, P; Xue, Y; Yang, C; Zhang, M, 2022) |
| "The presence of VM greatly hinders the treatment of glioblastoma (GBM) with anti-angiogenic drugs." | ( Dong, W; Liu, L; Liu, M; Liu, X; Ruan, X; Wang, D; Wang, P; Xue, Y; Yang, C; Zhang, M, 2022) |
| "However, its efficacy for the treatment of glioblastoma (GBM), a tumor type with a poor prognosis, has not yet been rigorously investigated." | ( Chen, A; Hu, Y; Huang, B; Li, X; Liu, G; Liu, X; Wang, J; Wen, M; Xue, Z; Yang, N; Zhang, X, 2023) |
| "Standard treatment for glioblastoma includes maximal safe resection followed by adjuvant radiation and concurrent temozolomide for 6 weeks, followed by 6 months of maintenance temozolomide; additionally, concurrent high doses of corticosteroids are required for many patients to reduce intracranial pressure and reduce inflammatory side effects." | ( Kleinberg, L; Kut, C, 2023) |
| "Pentamidine could be promising for the treatment of glioblastomas by targeting both glioma-initiating cells and differentiated cells through its multifaceted antiglioma effects." | ( Hirai, N; Hirao, A; Ichinose, T; Jiapaer, S; Kinoshita, M; Kobayashi, M; Nakada, M; Sabit, H; Tamai, S; Tanaka, S, 2023) |
| "The standard treatment of glioblastoma, an aggressive brain tumour, includes radiotherapy combined with temozolomide." | ( Henriksson, R; Kinhult, S; Löfgren, D; Rosenlund, L; Sandström, M; Strandeus, M; Tavelin, B, 2023) |
| "New approaches to the treatment of glioblastoma, including immune checkpoint blockade and oncolytic viruses, offer the possibility of improving glioblastoma outcomes and have as such been under intense study." | ( Craig, M; Fiset, B; Jenner, AL; Karimi, E; Quail, DF; Surendran, A; Walsh, LA, 2023) |
| "Apatinib might be effective in treating recurrent glioblastoma after chemoradiotherapy in terms of the overall response rate, but the efficacy is not durable and the clinical benefit is limited." | ( Liang, X; Lin, H; Sheng, X; Zhou, X, 2023) |
| "A critical challenge in the treatment of glioblastoma (GBM) is its highly invasive nature which promotes cell migration throughout the brain and hinders surgical resection and effective drug delivery." | ( Drummond, KJ; Kaye, AH; Mantamadiotis, T; Morokoff, AP; Stylli, SS; Whitehead, CA, 2023) |
| "Radiation is integral to the treatment of glioblastoma (GBM)." | ( Cappelli, L; Chen, Y; Liu, H; Miller, R; Niazi, M; Russial, O; Shi, W; Vakhnenko, Y, 2023) |
| "Temozolomide (TMZ) is a standard treatment for glioblastoma (GBM) patients." | ( Agnihotri, S; Cao, Y; Chen, D; Ding, F; Ge, X; Ge, Z; Huang, G; Ji, J; Lin, F; Lu, Z; Qian, X; Shi, Z; Wang, Q; Wang, X; Yin, J; You, Y; Zhang, J; Zhao, N; Zhou, Q, 2023) |
| "Temozolomide (TMZ) is standard treatment for glioblastoma (GBM); nonetheless, resistance and tumor recurrence are still major problems." | ( Franzmeier, S; Liesche-Starnecker, F; Schlegel, J; Wu, Y, 2023) |